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Every day you may make progress. Every step 
may be fruitful. Yet they will stretch out before you 
an ever-lengthening, ever-ascending, ever-improving 
path. You know you will never get to the end of the 
journey. But this, so far from discouraging, only adds 
to the joy and glory of the climb.
Sir Winston Churchill (1874 - 1965)
With the apparently unlimited propagation of its 
material power, humanity finds itself in the position of a 
captain, whose ship is built so strong with steel and iron, 
that the magnetic needle of his compass only shows the iron 
mass of the ship, but not anymore the North.
With such a ship one cannot reach a destination anymore; it 
would only navigate in a circle and therefore be delivered 
to winds and currents.
But to return to the situation of modern Physics: the danger 
only resides, as long as the captain does not know that his 
compass does not react anymore to the Earth’s magnetic 
forces.
[…]
Anyhow, to be conscious that the hope in the progress’s 
believe finds a limit, already includes the wish not to 
navigate in a circle but to reach a destination.
Werner Heisenberg (1901- 1976), translated from German: 
Das Naturbild der heutigen Physik. Hamburg: Rowohlts 
Deutsche Enzyklopädie 8, 1955, S. 22 
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Abstract
Total Hip Replacement (THR) is today a routine procedure executed more than
800’000 times per year worldwide. THR gives generally satisfactory results, although
the quality of outcome is inversely proportional to the age of the patient. In parallel,
there is a trend to propose cementless THR to patients younger than 60 years. These
patients have more demanding physical activity resulting in a significant increased
failure rate of the implants. In particular for these patients, the desired service life
of the implant should be extended.
Proximal peri-implant bone loss is generally observed during the first two years follow-
ing the implantation. This bone loss may lead to aseptic loosening, the major cause
of THR failure. In order to control peri-implant bone remodeling and in particular
the proximal bone loss, we developed the innovative concept of using the orthopedic
implant as drug delivery system (DDS). The cementless stem of a hip implant would
be coated with hydroxyapatite (HA) and bisphosphonate, a drug affecting bone re-
sorption. The basic idea is to biologically reduce the initial peri-implant bone loss
by decreasing the osteoclastic bone resorption activity. This approach could signific-
antly increase the THR outcome.
Pre-clinical tests were performed to numerically validate this new concept. An ex-
isting bone remodeling model was modified to take into account the bisphosphonate
effect. The outcome of a THR was evaluated with different simulated bisphosphonate
concentrations. Results of the simulations showed that the implant used as a drug
delivery system would increase bone density around the implant and decrease, at
the same time, the micromovements between the implant and the surrounding bone
tissue. Therefore, the evolution towards peri-implant bone loss and fibrous tissue
development at the bone-implant interface would be delayed, which could positively
influence the THR outcome. Pre-clinical tests allowed us to verify that a partial
proximal coating of the stem would result in a homogeneous bone remodeling, a situ-
ation biomechanically more favorable than the simulated situation obtained with a
full coating of the stem. Despite a numerically observed positive concentration effect,
it was noted that the decrease of peri-implant bone loss was most notably affected
with the intermediate simulated bisphosphonate concentration. Based on these pos-
itive pre-clinical results, in vitro and in vivo experiments were performed to further
validate the concept of orthopedic implant used as drug delivery system.
As bisphosphonates were developed for systemic delivery, little information was avail-
able regarding the bisphosphonate concentrations which could be safely used for a
local delivery application. It was especially important to quantify the bisphosphon-
ate concentration osteoblasts could be exposed to without harmful effect for the bone
formation process. We challenged osteoblasts from human and murine origins to dif-
ferent concentrations of the choosen bisphosphonate (Zoledronate from Novartis). As
wear particles are inevitably present in the peri-implant bone, we also added titanium
particles to quantify the eventual synergetic negative effect between Zoledronate and
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particles on osteoblast behavior. In this in vitro study, we showed that Zoledron-
ate did not impair proliferation of human osteoblasts when used at concentrations
lower or equal to 1 µM, while murine cells could be exposed to concentrations up
to 10 µM. A concentration of 0.01% of titanium particles did not impair prolifera-
tion of either cell line. Zoledronate affected, through a chelation phenomenon, ALP
activity of murine osteoblasts, whereas the presence of titanium particles strongly
decreased the ALP activity of murine osteoblasts. We did not detect any synergic
effect of Zoledronate and titanium particles on neither human and murine osteoblast
behavior. Those results allowed us to conclude that 1 µM and 10 µM Zoledronate
concentrations for human and murine respectively, could be used in the proposed
drug delivery system.
The basic idea behind the drug delivery system is that the bisphosphonate will stay
around the implant where its effect on bone resorption is needed. Since the drug
is directly brought into contact with the endosteal bone, it was necessary to study
the bisphosphonate diffusion in bone. The in vitro measured Zoledronate diffusion
profile in the bone showed that the bisphosphonate entered the bone and diffused
from the endosteal bone towards the periosteal bone. The drug accumulated in the
first millimeter of the endosteal bone. This meant that the Zoledronate would stay
in the peri-implant bone and would not reach regions which are not influenced by
the presence of the implant.
Based on the in vitro results for Zoledronate concentrations effect on osteoblast and
diffusion in bone, an in vivo experiment was designed to demonstrate the proof of
concept of orthopedic implant used as drug delivery system. Several Zoledronate
quantites were grafted to hydroxyapatite (HA) coatings of titanium implants. The
implants were inserted in rat condyles for 3 weeks. Bone density, histomorphomet-
ric and biomechanical measurements were performed on the collected rat femurs. A
concentration-dependent effect was observed on the peri-implant bone density and
on different histomorphometric parameters. The Zoledronate coated implant posit-
ively influenced the structure of the trabecular bone. Biomechanical pull-out tests
confirmed the higher peri-implant bone quality of Zoledronate coated implant. In-
terestingly, this in vivo study highlighted the existence of a window of Zoledronate
coating concentration in which the mechanical fixation of the implant was increased.
A similar result was suggested with the pre-clinical testing. The in vivo study allowed
the demonstration of proof-of-concept for orthopedic implant used as drug delivery
system to control peri-implant bone remodeling.
The results obtained in this thesis might then open the way of an easy transform-
ation of currently existing HA coated implants. By grafting bisphosphonate onto
the implant HA coating, the peri-implant bone loss might be reduced which would
increase the service life of a THR. This approach is especially interesting for patient
younger than 60 years.
Re´sume´
Le remplacement total de la hanche (RTH) est aujourd’hui une proce´dure de routine,
effectue´e plus de 800’000 fois par an a` travers le monde. Malgre´ les re´sultats satisfai-
sants de la RTH, la dure´e de vie de la prothe`se est inverse´ment proportionnelle a` l’aˆge
du patient. De plus, la tendance actuelle est de proposer des implants non-cimente´s
a` des patients de moins de 60 ans. Ces patients ont une activite´ physique plus exi-
geante re´sultant en un taux d’e´chec plus e´leve´. Pour cette cate´gorie de patients en
particulier, la dure´e de vie de l’implant devrait eˆtre allonge´e.
Une perte osseuse pe´ri-implant au niveau proximal est ge´ne´ralement observe´e durant
les deux premie`res anne´es suivant la pose de l’implant. Cette perte osseuse peut me-
ner au descellement aseptique de l’implant, cause principale d’e´chec de la RTH. Afin
de controˆler le remodeling osseux pe´ri-implant et en particulier celui de l’os proximal,
nous avons de´veloppe´ un concept innovatif utilisant l’implant orthope´didque comme
syste`me de relargage de me´dicament (Drug Delivery System, abbr. DDS). La tige
non-cimente´e d’un implant de hanche pourrait eˆtre reveˆtue d’hydroxyapatite et d’un
bisphosphonate, qui est un me´dicament affectant la re´sorption osseuse. L’ide´e de
base est de re´duire biologiquement la perte osseuse pe´ri-implant en diminuant l’acti-
vite´ de re´sorption osseuse des oste´oclastes. Cette approche pourrait significativement
ame´liorer les re´sultats des RTH.
Des tests pre´cliniques ont e´te´ effectue´s afin de valider nume´riquement ce nouveau
concept. Un mode`le nume´rique de remodelage osseux existant a e´te´ modifie´ pour
prendre en compte l’effet du bisphosphonate. Les re´sultats des RTH ont e´te´ e´value´s
avec diffe´rentes concentrations simule´es de bisphosphonates. Les re´sultats des simula-
tions ont montre´ que l’implant utilise´ comme DDS augmente la densite´ osseuse autour
de l’implant et diminue, en meˆme temps, les micromouvements entre l’implant et le
tissus osseux environnant. Ainsi, l’e´volution vers une perte osseuse pe´ri-implant et
une formation de tissu fibreux a` l’interface os-implant seraient retarde´es, ce qui pour-
rait influencer positivement les re´sultats obtenus avec la RTH. Les tests pre´cliniques
ont permis de ve´rifier qu’un reveˆtement proximal ge´ne´rerait un remodelage osseux
plus homoge`ne, c’est-a`-dire une situation biome´caniquement plus favorable que la
situation obtenue avec la simulation d’un remodelage osseux autour d’une tige tota-
lement reveˆtue. Malgre´ un effet positif de la concentration du bisphosphonate, il a e´te´
note´ que la diminution de perte osseuse pe´ri-implant est la plus prononce´e lors des
simulations de concentrations interme´diaires. Des expe´riences in vitro et in vivo ont
e´te´ effectue´es pour valider le concept d’utiliser des implants orthope´diques comme
DDS sur la base des re´sultats pre´cliniques positifs.
Comme les bisphosphonates ont e´te´ de´veloppe´s pour eˆtre administre´s de manie`re
syste´mique, peu d’informations e´taient disponibles concernant les concentrations de
bisphosphonates pouvant eˆtre utilise´es de manie`re suˆre lors d’une utilisation locale.
Il e´tait particulie`rement important de quantifier la concentration de bisphospho-
nate a` laquelle des oste´oblastes peuvent eˆtre expose´s sans influencer ne´gativement
la formation osseuse. Nous avons expose´ des oste´oblastes humains et de souris a`
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diverses concentrations d’un bisphosphonate particulier (Zoledronate de Novartis).
Comme des particules d’usure sont ine´vitablement pre´sentes dans l’os pe´ri-implant,
nous avons ajoute´ des particules de titane pour quantifier une e´ventuelle synergie
ne´gative entre le Zoledronate et les particules sur les oste´oblastes. Dans cette e´tude
in vitro, nous avons montre´ que le Zoledronate n’influence pas la prolife´ration des
oste´oblastes humains lorsque des concentrations infe´rieures a` 1 µM sont utilise´es alors
que les oste´oblastes de souris peuvent eˆtre expose´s a` des concentrations allant jus-
qu’a` 10 µM. Une concentration de 0.01% de particules n’a aucune influence sur les
deux ligne´es cellulaires. Par un phe´nome`ne de che´lation, l’activite´ de la phosphatase
alkaline a e´te´ influence´e par le Zoledronate. Par contre, la pre´sence de particules a
fortement diminue´ l’activite´ de la phosphatase alkaline. Aucune synergie n’a e´te´ me-
sure´e entre le Zoledronate et les particules de titane sur les deux ligne´es cellulaires.
Ces re´sultats nous permettent de pre´de´terminer qu’une concentration de 1 µM de Zo-
ledronate pourra eˆtre utilise´e dans le DDS propose´ pour des applications humaines
et de 10 µM dans le cas de souris.
L’ide´e a` la base du DDS est que le bisphosphonate reste autour de l’implant, la` ou` son
effet sur la re´sorption osseuse est ne´cessaire. Comme le me´dicament est directement
mis en contact avec l’os endoste´al, il est ne´cessaire d’e´tudier la diffusion du bisphos-
phonate dans l’os. Le profil de diffusion du Zoledronate mesure´ in vitro montre que
le bisphosphonate pe´ne`tre l’os et diffuse depuis l’os endoste´al vers l’os pe´rioste´al.
Le me´dicament s’accumule dans le premier millime`tre de l’os endoste´al. Ceci signifie
que le Zoledronate resterait dans l’os pe´ri-implant et n’atteindrait pas des re´gions du
squelette qui ne sont pas influence´es par l’implant.
Sur la base des re´sultats obtenus lors de l’e´tude in vitro de l’effet du Zoledro-
nate sur les oste´oblastes et de l’e´tude de la diffusion du Zoledronate dans l’os, une
e´tude in vivo a e´te´ conc¸ue pour de´montrer la validite´ du concept d’un implant or-
thope´dique utilise´ comme DDS. Diverses quantite´s de Zoledronate ont e´te´ greffe´es
sur le reveˆtement d’hydroxyapatite d’implants en titane. Ces implants ont e´te´ inse´re´s
dans des condyles de rats pendant 3 semaines. La densite´ ainsi que des parame`tres
histomorphome´triques ont e´te´ mesure´s sur les fe´murs de rats. Un effet de´pendant de
la quantite´ de Zoledronate a e´te´ mesure´ sur la densite´ osseuse et sur certains pa-
rame`tres histomorphome´triques. Les implants reveˆtus de Zoledronate ont positive-
ment influence´ la structure de l’os trabe´culaire. Des tests biome´caniques d’arrachage
ont confirme´ la meilleure qualite´ de l’os pe´ri-implant autour des implants reveˆtus de
Zoledronate. Il est inte´ressant de noter que cette e´tude in vivo souligne l’existence
d’un intervalle de concentration de Zoledronate contenu dans les reveˆtements avec
lesquel la fixation me´canique des implants est augmente´e. Un re´sultat similaire a e´te´
sugge´re´ par l’e´tude pre´clinique. L’e´tude in vivo permet de de´montrer la validitite´ du
concept d’utiliser l’implant orthope´dique comme DDS pour le controˆle du remodelage
osseux pe´ri-implant.
Les re´sultats obtenus durant cette the`se ouvrent le chemin pour une transformation
simple d’implants orthope´diques reveˆtus d’hydroxyapatite. En greffant un bisphos-
phonate sur l’implant reveˆtu d’hydroxyapatite, la perte osseuse pe´ri-implant pourrait
eˆtre re´duite et augmenterait ainsi la dure´e de vie des RTH. Cette approche est par-
ticulie`rement inte´ressante pour des patients de moins de 60 ans.
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Introduction
1.1 Clinical background in Total Hip Replacement
More than 40 years ago, Sir Charnley started a revolution in orthopedics. He treated
hip fractures by inserting a metallic stem into the femur articulated against an acetab-
ular cup placed in the hip10. This surgical procedure, called Total Hip Replacement
(THR), is today a routine procedure executed more than 800’000 times per year
worldwide34. THR becomes necessary when the joint is damaged to an extent that it
cannot fullfill its function or if the use of the joint is too painfull. The fixation of the
stem in the femur can either be performed by a polymeric cement (cemented THR)
or by mechanical pressure by inserting a stem slightly bigger than the medular canal
(uncemented THR). Three main types of stems are used (see Figure 1.1): straight,
Straight stem Anatomical stem
(collarless)
Anatomical stem
(collared)
Figure 1.1: Photographies of a straight stem, an anatomical collarless stem and an
anatomical collared stem for an uncemented hip implant.
anatomical (collarless), anatomical shape (collared) shape design.
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1.1.1 Outcome of THR
In some countries, the outcomes of THR are collected in a National Register. The
Swedish National Hip Arthroplasty Register (SNHAR) is the most comprehensive
and rigorous hip arthroplasty register in the world with more than 216’000 implants
followed since 1979. The data presented are obtained from the SNHAR 2002 report39.
The average swedish patient is 70 years old and is treated for osteoarthritis. The av-
erage age of the patients is slightly decreasing. The majority of the patients are above
60 years (82.6% of all THR patients). The patients younger than 59 years account
for 17.4% of all the THR patients.
Between 60 and 75 years
In this age class, most of the patients are treated with a cemented stem (97%), while
uncemented stems are implanted rarely (3%). After 11 years of implantation, the
cemented stems have a survival rate of 93% (see Figure 1.2(a)) while 79% of the un-
cemented stems could stay implanted (see Figure 1.2(d)). In the period 1992-2002,
a total of 95’366 implants were inserted in Sweden in this age class.
Between 50 and 59 years
In this age class, most of the patients are treated with a cemented stem (68%), while
uncemented stems are less implanted (28%). After 11 years of implantation, the
cemented stems have a survival rate of 88% (see Figure 1.2(b)) while 83% of the
uncemented stems could stay implanted (see Figure 1.2(e)). In the period 1992-2002,
a total of 14’765 implants were inserted in Sweden in this age class.
Younger than 50 years
In this age class, almost the same share of patients are treated with a cemented stem
(47%) or an uncemented stem (48%). After 11 years of implantation, the cemented
stems have a survival rate of 83% (see Figure 1.2(c)) while 74% of the uncemented
stems could stay implanted (see Figure 1.2(f)). In the period 1992-2002, a total of
5’403 implants were inserted in Sweden in this age class (see Figures 1.2).
Limitations of SNHAR
The numbers given in this report underevaluate the real number of needed revi-
sions, since only the performed revisions are taken into account. Hence, the patients
with pain below their pain threshold, the ones on the waiting list and the ones with
a starting loosening (radiolucent line around the implant) are not taken into account.
1.1.2 Complications
There are mainly two complications encountered in relation with THR :
1. Aseptic loosening (Osteolysis): characterized by a decrease in bone volume
and by a 2 mm gap between prosthesis and bone as seen in radiographies from
arthroplasty patients12.
2. Osteopenia induced by stress-shielding: less than normal amount of bone res-
ulting from the stress-shielding of the bone by the high stiffness of the metallic
stem.
- 3 -
Chapter 1
70
75
80
85
90
95
100
Male, 11y=92,0% (91,1-92,8), n=21 968
Female, 11y=94,3% (93,7-95,0), n=31 289 
Between 60 and 75 years
Cemented Implants, 1992-2002
9876543210 10 11
years postoperatively
p
ro
p
o
rt
io
n
 r
e
vi
se
d
C
o
p
y
ri
g
h
t©
 2
0
0
3
 T
h
e
 S
w
e
d
is
h
 N
a
ti
o
n
a
l H
ip
 A
rt
h
ro
p
la
st
y
 R
e
g
is
te
r
(a) Cemented implants
in patients between 60
and 75 years
Between 50 and 59 years
Cemented Implants, 1992-2002
70
75
80
85
90
95
100
9876543210 10 11
years postoperatively
p
ro
p
o
rt
io
n
 r
e
vi
se
d
Male,11y = 96,5% (96,0-97,0), n=11 350
Female,11y = 97,4% (97,2-97,7), n=24 352 
C
o
p
y
ri
g
h
t©
 2
0
0
3
 T
h
e
 S
w
e
d
is
h
 N
a
ti
o
n
a
l H
ip
 A
rt
h
ro
p
la
st
y
 R
e
g
is
te
r
(b) Cemented implants
in patients between 50
and 59 years
Younger than 50 years
Cemented Implants, 1992-2002 
70
75
80
85
90
95
100
Male, 11y=85,9% (81,2-90,5), n=1 063
Female, 11y=80,5% (73,6-87,5), n=1 369 
9876543210 10 11
years postoperatively
p
ro
p
o
rt
io
n
 r
e
vi
se
d
C
o
p
y
ri
g
h
t©
 2
0
0
3
 T
h
e
 S
w
e
d
is
h
 N
a
ti
o
n
a
l H
ip
 A
rt
h
ro
p
la
st
y
 R
e
g
is
te
r
(c) Cemented implants
in patients younger than
50 years
70
75
80
85
90
95
100
Male, 11y=78,9% (70,1-87,8), n=310
Female, 11y=80,6% (62,7-98,6), n=216
Between 60 and 75 years
Uncemented Implants, 1992-2002
9876543210 10 11
years postoperatively
p
ro
p
o
rt
io
n
 r
e
vi
se
d
C
o
p
y
ri
g
h
t©
 2
0
0
3
 T
h
e
 S
w
e
d
is
h
 N
a
ti
o
n
a
l H
ip
 A
rt
h
ro
p
la
st
y
 R
e
g
is
te
r
(d) Uncemented im-
plants in patients
between 60 and 75 years
70
75
80
85
90
95
100
 
Between 50 and 59 years
Uncemented Implants, 1992-2002
9876543210 10 11
years postoperatively
p
ro
p
o
rt
io
n
 r
e
vi
se
d
Male,11y = 85,2% (80,5-89,9), n=786
Female,11y = 81,0% (74,4-87,6), n=791
C
o
p
y
ri
g
h
t©
 2
0
0
3
 T
h
e
 S
w
e
d
is
h
 N
a
ti
o
n
a
l H
ip
 A
rt
h
ro
p
la
st
y
 R
e
g
is
te
r
(e) Uncemented im-
plants in patients
between 50 and 59 years
70
75
80
85
90
95
100
Male, 11y=77,9% (71,4-84,4), n=589
Female, 11y=72,4% (660-78,8), n=675 
Younger than 50 years
Uncemented Implants, 1992-2002 
9876543210 10 11
years postoperatively
p
ro
p
o
rt
io
n
 r
e
vi
se
d
C
o
p
y
ri
g
h
t©
 2
0
0
3
 T
h
e
 S
w
e
d
is
h
 N
a
ti
o
n
a
l H
ip
 A
rt
h
ro
p
la
st
y
 R
e
g
is
te
r
(f) Uncemented im-
plants in patients
younger than 50 years
Figure 1.2: The report 2002 of the SNHAR gives the survival curves for the different
fixation types and the different patient age classes.
1.2 Aseptic loosening
Two parameters are playing a role in aseptic loosening : the load transfer through
the bone/implant interface and the wear rate at all implant’s interfaces.
1.2.1 Force transfer
The force transfer between the implant and the bone is of uttermost importance.
If the distribution of the stresses is not appropriate (i.e. contact in form of ”spot-
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welds”112), locally high stresses lead to the fracture of the bone/implant interface5.
The degradation of the peri-implant, which role is to hold the implant in place, fails
more and more, increasing the wear at all interfaces and wear couples. The following
cascade of events tends to replace the peri-implant bone by fibrous tissue, in the
places where the implant/bone interface has failed.
1.2.2 Biological reactions
Peri-implant osteolysis has been associated with the generation of billions of wear
debris particles that become embedded in the surrounding tissue. These particles
are generated by the friction at all implant interfaces inducing a biological reaction
that may lead to osteolysis. As many as 109 particles per gram of tissue92, 56, 59
have been retrieved. The presence of wear debris activate macrophages, which try to
eliminate the particles by phagocytosis. This results in the secretion of proinflam-
matory cytokines such as tumor necrosis factor α (TNF-α), interleukines (Il-1 and
Il-6). Release of these cytokines leads to an inflammatory response characterized by
the recruitment and activation of osteoclasts to the bone/implant interface and the
formation of a periprosthetic membrane67, 66, 43 which shares some histological fea-
tures with the pannus in rheumatoid arthritis93. The increased osteoclastic activity
will lead to a higher bone resorption. Moreover, the presence of debris also influ-
ences the bone formation (Figure 1.3). Wear particles were recently demonstrated
to influence in vitro the osteoblasts behavior115, 77, 107, 118 and may then be involved
in the situation of decreased peri−implant bone formation. Lohmann showed that
particles were found intracellularly in osteoblasts, primarily in the cytosol, leading to
extensive deformation and damage to organelles when compard to untreated cells55.
Particles also inhibited osteoblast function assessed by a diminution of the develop-
ment of mineralized nodules and alkaline phosphatase positive colony area3.
Thus, the presence of particles increases bone resorption and decreases bone form-
ation, resulting in a bone remodeling shifted towards resorption. Osteolysis is a
consequence of a tissular and biological reaction to the presence of debris.
The peri-implant bone resorption leads to a progressive loosening of the implant,
resulting in increased micromotion between the bone and the implant. Two con-
sequences are observed. First, the peri-implant tissue fills the gap by creating a
fibrous tissue at the places where the bone-implant contact is lost. Secondly, the mi-
cromotions will generate metallic wear debris. These particles are going to increase
the disequilibrium between bone formation and bone resorption. The loosening there-
fore increases. The bone-implant system then enters a vicious cycle.
1.3 Proximal osteopenia due to stress-shielding
The presence of an implant in the hip affects the normal bone remodeling by changing
the stress distribution in the bone.
Stress-shielding consists in the reduction of the mechanical forces stimulating the
bone as compared to a not implanted bone due to the high stiffness of the metallic
- 5 -
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Macrophage
Osteoclast
Osteoblast
Particles
Bone 
Formation (-)
Bone 
Resorption 
(+)
Viability (-)
Proliferation (-)
Collagen (-)
ALP (-)
MMP
IL-1α, β
TNF-α
Nitric Oxyde
Il-6
PGE
2
Chemokine
Lysosmal 
enzyme
Osteolysis
Figure 1.3: The presence of wear particles influences different cell types present at
the bone-implant interface. On one side, the macrophages try to digest the particles.
This reaction attracts other macrophages and increases the release of cytokines (like
interleukines, TNF-α,...). In addition, these cytokines increase the number and the
activity of osteoclasts. Therefore the bone resorption increases. Then, the particles
have a toxic effect on osteoblats resulting in decreased viability, proliferation, Alkaline
phosphatase (ALP) activity and collagen production. The (-) and (+) shows the
decrease or increase of the mentionned variables.
implant. The proximal femur is mechanically under-stimulated and resorbs6 (see
Figure 1.4).
Conforming to Wolff’s law and the biological process of remodeling, the bone density
around an implant decreases. The mechanical under-stimulation of the peri-implant
bone is responsible for the bone loss. The under-stimulation is more marked with
increasing stem diameter23 and with increasing distal leaning79. The adaptation of
the bone to the mechanical forces is performed by the remodeling process.
1.3.1 Remodeling
Bone adapts to its mechanical and biological environment by modifying its density
and architecture (see Figure 1.5). From a conceptual point of view, the functional
unit performing these adaptations has been called Basic Multicellular Unit (BMU).
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Figure 1.4: X-ray images of a femur, immediately (a) and one year (b) after THR6,
showing the proximal resorption and the distal densification due to stress shielding.
Figure 1.5: Adaptation of bone structure to mechanical function along lines of pres-
sure and tension. The bone structure aligns itself to offer the best mechanical
resistance to the applied forces. When the direction of the forces changes over a
longer period of time, bone adapts to the new mechanical situation and changes
the orientation of the bone trabeculae. M, muscle pull; R, down direction of load.
(Adapted73, 29)
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Figure 1.6: Temporal representation of the bone remodeling sequence in trabecular
bone. The points 1 to 6 have to be seen as timepoints and not as locations on the
bone. The bone resorption consists of an osteoclastic phase (1), a mononuclear phase
(2) and a preosteoblastic phase (3). The final erosion depth is reached in phase (3).
After recruitment of preosteoblasts (3), bone formation starts with formation of an
unmineralized matrix (osteoid) (4), which subsequently undergoes mineralization (5).
The final thickness (mean wall thickness) of the new bone is reached at the end of the
formative period (6), where the thin osteoblasts transforms into lining cells. These
different processes can occur at same place but are well separated in time26.
Macroscopic description
The understanding of the bone remodeling is based on the concept of BMU (Figure
1.6) defined by Frost in 196331. The BMU is composed of osteoclasts (which resorbs
bone at the cutting edge of the unit) and osteoblasts (which form bone behind the
osteoclasts). The resulting effect is to renew the old bone containing fatigue micro-
cracks by new crack-free bone. The life time of a BMU is about 200 days and during
this time it moves over 4000 µm. This process is active in periosteal, endosteal and
trabecular surfaces as well as within cortical bone.
Six phases can be distinguished in the bone remodeling by a BMU :
• Activation : Differentiated cells must be recruited before any bone resorption
and formation can occurr.
• Resorption : Osteoclasts are lined up in the cutting cone named after its half-
eggshell shape with a diameter of 200 µm and 300 µm long. The osteoclasts
move forward with a rate of 20 µm/day.
• Reverseal : The osteoclastic activity switches to osteoblastic activity in the
reverseal region. The surface of this region will form the cement line, or re-
verseal line, of the osteon (osteons are modified vascular channels resulting of
sequential layers of bone). In humans, the resorption and reverseal periods can
take about 30 days.
- 8 -
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• Bone formation : Osteoblasts become active (either derived from mesenchymal
cells or reactivated lining cells) at the periphery of the resorption tunnel left
behind the reverseal zone and start to form bone. The new matrix, mainly
made of collagen type I, is deposited as concentric lamellae at a decreasing rate
when moving towards the center of the tunnel. Since the cells need nutrients,
the osteoblasts do not completely refill the tunnel. This passage becomes then
part of the haversian system. It stays at an internal diameter of 40 to 50 µm.
• Mineralization : The deposited matrix is unmineralized and is called osteoids.
The mineralization consists of the deposition of mineral within and between the
collagen fibers. There is a 10 days period between the deposition of the matrix
and its mineralization. Twenty-four hours after the beginning of the mineral-
isation, 60% of the matrix are mineralized. The mineralization is completed in
the following 6 months72.
• Quiescence : Once the refilling and the mineralization of the tunnel is complete,
the osteoclasts enter apoptosis and the osteoblasts become either osteocytes
(entrapped in the bone matrix) or haversian lining cells (at the bone surface)
or enter the apoptotic phase.
Cellular level
As mentionned, BMUs contain osteoclasts, osteoblasts, osteocytes and lining cells:
• Osteoclasts are responsible for the resorption of bone. They originate from the
hematopeitic lineage, more precisely form the granulocyte-macrophage colony-
forming unit. They dissolve bone by creating a sealed volume between the
osteoclast and the bone. This resorption volume is delimited by an actin rich
ring. In a first step, the sealed volume’s fluid becomes acid due to the release
of H+ ions from the osteoclasts into the volume’s fluid. Therefore the bone
mineral dissolves below the cell. In a second step, enzymes like collagenase, are
released into the cavity to dissolve the organic extracellular matrix.
• Osteoblasts are cells that derive from mesenchymal stem cells. They are re-
sponsible for the bone formation by deposing a collagen composed extracellular
matrix. This matrix is mineralized in a second step. Once the bone formation is
temporarily halted, the osteoblasts become either trapped in the extracellular
matrix or stay at the surface of the bone or enters the apoptosis process.
• Osteocytes are the bone matrix embedded former osteoblasts. They are in-
terconnected with each other by canaliculi containing cell processes. They are
probably involved in the homeostasis of bone fluid and in the homeostasis of
plasma calcium. They also may play an important role in the bone response
to mechanical stimuli.
• Lining cells are resting and flattened inactive osteoblasts which can be recruited
for later bone formation.
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In BMU, cells interact with each other through the means of cytokines and growth
factors in order to guarantee that each cell type executes the right task at the right
moment and in the right place.
One important parameter for the activation of BMU is the mechanical stimulus. In-
deed, Frost32 has proposed, and experimental evidence indicates57 the existence of
thresholds or set points for mechanical stimuli to influence bone remodeling. Low
level of mechanical strain (0-250 µ) are not sufficient to maintain the bone mass as
bone resorption exceeds bone formation. Mechanical strains in the range of 250-2500
µ provide adequate stimulation for bone tissue to be maintened. Above 2500 µ,
bone formation is stimulated, however, damage to the bone tissue begins to occur
in response to these supraphysiologic mechanical loads. Frost also speculates that
certain hormones or biochemical agents may alter these thresholds, allowing nor-
mal mechanical usage to stimulate the bone formation. Several studies suggest one
factor, parathyroid hormone, which could enable bone tissue to be maintained and
even be produced at lower magnitudes or mechanical strains. Recently, a growing
body of evidence tends to demonstrate that the fluid flow within the canaliculae and
lacunae of bone is primary responsible for mechanochemical signal transduction in
bone cells52.
Molecular level
Bone remodeling is regulated by systemic hormones and by local factors, which affect
the cells of the osteoclast or the osteoblast lineage and exert their effects on i) the
replication of undifferentiated cells, ii) the recruitment of cells, iii) the differentiated
function of cells9. The local factors are synthesized by skeletal cells and include
growth factors, cytokines and prostaglandins. The hormones that regulate bone
remodeling are:
• Polypetide hormone
– Parathyroid hormone (PTH)
– Calcitonin (inhibits bone resorption)
– Insulin (stimulates bone matrix synthesis and necessary for bone mineral-
ization)
– Growth hormone (limited action)
• Steroid hormones
– 1,25-Dihydroxyvitamin D3 (necessary for bone mineralization)
– Glucocorticoids (decrease bone collagen and matrix)
– Sex steroid: estrogens (decrease bone resorption), androgens
• Thyroid hormones (stimulate bone resorption)
The skeletal growth factors are:
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• Insulin-like growth factor (IGF) (enhances bone collagen and matrix synthesis)
• TGF-β family of peptide (enhances bone collagen synthesis and decreases bone
resorption)
• Fibroblast growth factors (FGF) (enhances bone collagen synthesis)
• Il-1, Il-4, Il-6, Il-11 (stimulate bone resorption)
• TNF (stimulates bone resorption)
• CSF (stimulates bone resorption)
Recently, molecular factors influencing the osteoclast differentiation have been identi-
fied with the RANK/RANKL/OPG signaling pathway7, 49, 95. In parallel, it has been
shown that CSF-1 is required for the initiation of differentiation by uncommitted os-
teoclast precursor in bone marrow33, 51. RANKL and OPG are highly expressed in
osteoblast/stromal cells, their expression can be upregulated by the bone resorbing
factors vitamin D3, Il-11, PGE2 and PTH
116. CSF-1 is also expressed by osteoblast
cells.
The osteoclastogenesis being under control of preosteoblastic/stromal cells, ensures
that the bone resorption and the bone formation will be tightly coupled. This coup-
ling allows for a wave of bone formation to follow each cycle of bone resorption, thus
maintaining skeletal integrity91. Further coupling between osteoblastogenesis and
osteoclastogenesis is ensured by the fact that the osteoblast differentiation factor,
cbfa1, is necessary for adequate expression of the osteoclast differentiation factor,
RANKL, on the surface of preosteoblastic/stromal cells46. RANKL is critical for
the differentiation, fusion into multinucleated cells, activation, and survival of osteo-
clastic cells. OPG brakes the entire system by blocking the effects of RANKL.
Physiologically, OPG may accumulate to some extent in the bone matrix and is
able to block the osteoclast formation. The osteoclast formation may be determined
principally by the RANKL/OPG ratio in the bone marrow environment40.
1.4 What are the common points between osteopenia
and osteolysis ?
The common point between osteolysis and osteopenia are the actors implicated in
both phenomena : the osteoclasts13, 89, 45, 80. These bone cells are the major contrib-
utors to the aseptic loosening and failure of the implant. Therefore, the osteoclasts
become the priviliged target of a strategy developed to increase the service time of
THR. Thus the developed strategy to reduce the peri-implant osteolysis is to decrease
the bone resorption, hence the osteoclastic activity. By using a drug that influences
osteoclasts, we aim at decreasing the bone resorption due to either stress-shielding
or osteolysis. Therefore, the aseptic loosening could be decreased and the implant
survival increased.
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Figure 1.7: Chemical structure of Zoledronate, the most recent and potent of the
bisphosphonate family.
1.5 Drug affecting bone resorption
The main principle targeted by the drugs affecting bone remodeling is to decrease
the catabolic activity in bone. Different classes of drugs exists.
Estrogens and selective estrogen receptor modulators (SERMs) treatement clearly
inhibits bone loss as well as bone turnover. An increase in bone mineral density69
may be obtained. But this treatment also affects other tissues including breast and
uterus. Moreover, these compounds are suspected to increase the risk of cancer in
those tissues68.
Calcitonin is a polypeptide hormone that inhibits bone resorption by acutely block-
ing osteoclast activity17. Because calcitonin is a protein, it cannot be taken orally as
it would be digested before it could reach the targeted region.
The bisphosphonates are decreasing, but not suppressing, the bone resorption by
acting on the osteoclasts83. This class of drugs acts on the number of osteoclast
by pushing them towards apoptosis. The bisphosphonates decrease the efficiency of
the osteoclasts by disrupting the actin ring around the ruﬄed border need for the
resorption. Moreover it seems that the stiffness of the membrane is higher when
bisphosphonates are present90. This is due to the inhition action of the bisphosphon-
ates on the mevalonate pathway which is part of the cholesterol production104, 85.
Cholesterol increases the elasticity of the cell membrane and therefore the shape ad-
aptibility of the membrane14.
Bisphosphonates are compounds characterized by two C-P bonds located on the same
carbon atom. The P-C-P structure allows a great number of possible variations,
either by changing the two lateral chains on the carbon atom, or by esterifying the
phosphate groups. Each bisphosphonate created in this way (see Figure 1.7 for the
structure of the latest developed bisphosphonate, called Zoledronate) has its own
physicochemical and biological characteristics. The P-C-P bonds of the bisphos-
phonates are stable to heat and most chemical reagents, and completely resistant to
enzimatic hydrolysis, but can be hydrolyzed in solution by ultraviolet light. These
compounds have a strong affinity for metal ions (like calcium), with that they can
form both soluble and insoluble complexes and aggregates, depending on the pH of
the solution and the metal present.
Bisphosphonates are already successfully used in the treatment of osteoporosis29. Dif-
ferent forms, such as ibandronate30, EDPH71, Zoledronate4, TRK-53042 and alendronate113,
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have been extensively studied and demonstrated their antiresorptive effect.
The decision to use bisphosphonate to control the peri-implant bone remodeling is
based on its clinical success in treating diseases leading to bone resorption.
1.5.1 Systemic drug delivery of bisphosphonate to decrease
peri-implant osteolysis
Recently, one way that was suggested to decrease the peri-implant osteolysis, was
to use a bisphosphonate94. The main drawback of the bisphosphonate is its low
oral bioavailability. Typically, only 1% of the administrated doses is absorbed in
the gastro-intestinal track while 30-80% of the intravenously adminstrated doses is
excreeted by the urine27.
Some clinical studies have verified the positive effect of a systemic bisphosphonate
treatement on the peri-implant bone density111. Wilkinson showed that a single infu-
sion of 90 mg of alendronate allowed to increase significantly the periprosthetic bone
density. Moreover, this kind of treatment allows to treat osteoporosis at other parts
of the skeleton than the one containing the implant.
But in cases of patients not suffering from osteoporosis, the bisphosphonate treate-
ment should not affect the whole skeleton, but should target the bone containing the
implant.
Side-effects like fever63, 103, throat or stomach ulcers22 as well as a low bio-availability
are generally observed for systemic bisphosphonate treatment.
1.5.2 Local drug delivery to decrease peri-implant osteolysis
Due to the high specificity to bone attachement of the bisphosphonates, they become
a very interesting candidate for the use of a local treatement in bone.
In order to avoid the side-effects related to the systemic delivery and to increase the
bisphosphonate bioavailability, local delivery of bisphosphonates could be considered.
Moreover in this configuration, the bone in contact with the implant will be the only
one to be treated, allowing to target specific part of the skeleton. The local drug
delivery strategy has been tested in vivo with no negatif effects but only slight in-
crease in implant osteointegration for dental implants60, 61 or for bulk hydroxyapatite
blocks18, 19.
Local injections of TKR (a bisphosphonate) close to the implant showed that the
osteolysis around the implant and the particle related expresion of Il-1α were signi-
ficantly decreased. Moreover the number of active osteoclasts decreased with the use
of the bisphosphonate by a factor 3 to 642. Yoshinari117 used plasma sprayed HA
coated titanium dental implant which were immersed in pamidronate and implanted
in beagle mandibulars. This study could show a 10% increase in bone contact area.
Tengvall99 showed a 28% increase in pullout force and 90% pullout energy when
comparing stainless steel screws with the same type of screws but coated with a fib-
rinogen coating containing pamidronate and implanted in rat tibia. Upon immersion
of HA coated titanium in a bisphosphonate solution, an increased bone contact was
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indicated in dogs after 4-12 weeks of implantation of the coated titanium, although
no testing of mechanical anchorage was then performed19.
Actually no information can be found about the optimal bisphosphonate quantity
needed to achieve an optimal control of peri-implant bone remodeling, specifically
for orthopedic implant stability. The local delivery of bisphosphonates in bones has
only been quantified in a few studies and none of them addresses the problem of en-
hancing the secondary stability of the implant by using an implant as drug delivery
system.
1.6 Conclusion
As shown in the previous paragraphs, two different phenomena lead to peri-implant
bone loss :
1. Osteolysis and osteopenia induced by stress-shielding lead to bone loss
2. Eventhough both phenomena result in a decreased bone density, the mechan-
isms are different but the main actors are the same, hence the osteoclasts
3. Previous work tried to decrease the stress-shielding by changing the desing of
the implants
4. Certain developmental work on solving the problem of wear was conducted with
the focus on alternative bearing surfaces that are more resistant to wear
5. The present work is not refusing those solutions but tries to influence the bio-
logical actors by using locally an anti-resorptive drug in order to improve the
outcome of THR.
1.6.1 Rationale for orthopedic implant used as drug delivery
system
A faster mechanical fixation is expected to improve the functionality of a prosthesis
due to an earlier and higher mechanical load uptake, a decrease of the thickness of the
fibrous encapsulation in soft tissues, and improved interfacial neovascularization100.
Early micromotion, which is associated to risk of late loosening could also be min-
imized.
The main part of the bone resorption takes place during the first two years of
implantation24. The causes are the stress-shielding and the wear particles origin-
ating from the acetabular cup. As mentionned, these factors lead to loosening which
in turn accelerates the peri-implant osteolysis. Control of peri-implant bone remod-
eling and in particular inhibition of bone resorption should be done immediately
post-operatively to keep the peri-implant bone quality. The basic hypothesis is that
by conserving the peri-implant bone quality during the first years following the im-
plantation, the implant outcome may be greatly improved.
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Figure 1.8: Pathway followed during the thesis.
To use the bisphophonate in an efficient way, the use of the implant as drug delivery
system is suggested. The vector for the bisphosphonate will be a hydroxyapatite
(HA) coating. The hydroxyapatite coating has been used in orthopedic surgery for
over 15 years in uncemented joint replacement25. Initially, it was setup to accelerate
the peri-implant bone formation and thus decrease the time needed to obtain a sat-
isfactory secondary fixation of the implant. Since then, it has been shown that the
HA coating improves the stability of the implant, the interface strength, the bone
mineralization and the bone ingrowth rate96. Specifically, Adler1 showed that HA
coating increased the fatigue resistance of the bone-implant interface. The interface
between the coating and the implant may become the weakpoint of the system70.
This problem was solved by decreasing the HA coating thickness109.
HA coatings used in animal and human studies indicate that the interfaces are char-
acterized by a relatively low calcium phosphate solubility over time100. New bone
mineral deposition is suggested to occur from the surface and outwards leading to
early functional loading capability, compared to surfaces without the coating.
Using orthopedic implant as drug delivery system may then be an ideal solution from
the biological point of view, as well as from the surgical point of view, this approach
implies no change of the standard surgical techniques.
1.6.2 Thesis objectives
The outcome of THR may be increased, especially for patients younger than 60
years. For these patients, the use of cementless implant is especially appropriated.
The clinical objective for the development of a new hip implant should be to control
the initial post-operative bone remodeling in order to avoid the proximal osteolysis.
The primary objective of this thesis is then to develop and to demonstrate the proof
of concept of an orthopedic implant used as drug delivery system. This new concept
of orthopedic implant combines actual implant designs with active biological agents.
The development of this implant should then follow the successive steps described in
Figure 1.8. In particular for this thesis, the following steps will be performed :
1. Numerical and theoretical evaluation of the concept of implant as drug delivery
(Figure 1.8, square 1, Chapter 2).
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2. Determine the Zoledronate concentration which does not decrease the osteo-
blastic activity (Figure 1.8, square 2, Chapter 3).
3. Quantify the Zoledronate diffusion in bone (Figure 1.8, square 3, Chapter 4).
4. Establish a proof of concept for the orthopedic implant used as drug delivery
system (Figure 1.8, square 6, Chapter 5).
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Numerical validation of orthopedic
implant as DDS
2.1 Goals
In the present chapter, with a theoretical approach, the concept of using drugs to
influence bone remodeling around an orthopedic implant was tested. The goals are
to theoretically validate the concept of an orthopedic implant used as drug delivery
system, to compare the systemic and the local drug delivery on peri-implant bone
remodeling and to determine the region on the stem to be coated to achieve an
optimal bone distribution.
2.2 Flowchart
The strategy applied to study the bisphosphonate effect on the peri-implant bone
remodeling is shown in Figure 2.1. First, the effect of a systemic alendronate
treatement has been studied by using remodeling paramaters identified from clin-
ical studies76, 53, 111. Secondly, the effect of locally applied bisphosphonate has been
studied. Two configurations have been explored : full stem coating and partially
coated stem.
2.3 Model of bone remodeling
The developed bone remodeling model is based on an existing model102 which links
the bone density evolution to the mechanical stresses experienced by the bone. This
model used the concept of relative bone density. Within a given volume, the relative
density is the mass of bone tissue contained in this volume divided by the mass of
mineralized matrix that would occupy the same volume. The bone mineral content
is the ratio of the unit weight of the mineral phase of bone to the unit weight of
dry bone (60-70% for cortical bone). Specifically, the temporal evolution of the
relative bone density φ˙ = ∂φ
∂t
is linked to the mechanical stimulus ψ applied to the
bone, by a piecewise linear evolution relation (Figure 2.2). The bone inhomogeneity
and the bone transverse isotropic symmetry is taken into account by the use of
two field variables: the relative bone density φ and the anisotropy tensor M. This
tensor allows to take into account the anisotropy of bone, hence the dependence of
mechanical properties as function of directions. The anisotropy tensor M is kept
constant with time. This hypothesis is justified by the fact that the time period over
which our model runs, is short as compared to the rate of variation of the anisotropy
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Figure 2.1: Flow chart describing the strategy applied to study the bisphosphonate
effects on peri-implant bone remodeling.
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Figure 2.2: Bone relative density evolution in function of mechanical stimulus.
in human bone20. In a period of ten years, the anisotropy changes by about 10%
while our model is simulating duration of about 1.5 years21. Moreover, numerically,
changes in time of the anisotropy tensor did not significantly change the results. The
invariability of M over time allows to shorten the calculation time101. In long bones
like the femur, the anisotropy tensor can be considered as spatially constant20, 21.
The piecewise linear function relating the bone remodeling rate to the mechanical
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stress is composed of three parts:
1. A resorption zone, when the bone is subjected to a mechanical stimuli below
the resorption threshold ψr. The resorption rate increases as a linear function
of the stress along a slope vr.
2. An equilibrium zone, where bone neither resorbs nor densifies. The equilibrium
zone is delimited by two threshold stimuli ψr and ψd.
3. A densification zone, when the bone is subjected to a mechanical stimuli above
the densification limit ψd. The resorption rate increases as a linear function of
the stress along a slope vd. The curve ends with a plateau highlighting the fact
that the bone densification speed cannot exceed a certain rate. This plateau
was set to φ˙max=0.25 week
−1.
The adaptation function for the bone density is therefore determined by the four
parameters ψr, vr, ψd and vd. ψ was set to a plastic yield stress
102, which is a
way of measuring the microdamage, since plastic deformations are needed to create
microcracks101. The equation describing the bone adaptation behaviour in our model
is50, 20:
φ˙ =


vr(ψ − ψr) if ψ < ψr
0 if ψr ≤ ψ ≤ ψd
vd(ψ − ψd) if ψ > ψd
(2.1)
2.4 Incorporation of bisphosphonate effects into
the bone remodeling model
2.4.1 Hypothesis
The following hypothesis were taken into account:
• No transport of the bisphosphonate which means that the drug binds to the
bone mineral.
• The bisphosphonate has no influence on bone densification.
2.4.2 Model of the drug effect
Drugs used to control the disease of bone metabolism, e.g. bisphosphonates, affect
the bone turnover29. This can be modeled by transforming the four main parameters
vr, ψr, vd and ψd as functions depending on the drug effect.
vr(κ) = vr · κ (2.2)
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The factor kappa is a value between 0 and 1 which is defined for each location in
the bone and can be dependent upon the drug concentration or other biological
properties. The dependencies for ψr(κ), vd(κ) and ψd(κ) are defined in the same
way. The implementation of the drug altering the bone remodeling parameters (Eq.
2.1) has been achieved by using a set of parameters vr(κ), ψr(κ), vd(κ) and ψd(κ)
calculated with Eq. 2.2.
For the present study, this dependency has been arbitrarily set to a linear relation
(Eq. 2.2). To model the effects of bisphosphonate, the values of the resorption
parameters ψr and vr were affected. The formation parameters ψd and vd are kept
constant since clinically and numerically, in a situation of peri-implant osteolysis,
they have only very small effects on the temporal evolution of bone density or on bone
properties. In this description, it is assumed that bisphosphonate has no effect on
the bone formation parameters. This point has been confirmed for bisphosphonates
such as alendronate11.
2.4.3 Drug delivery mode
Placebo case
The numerical values used for the normal bone remodeling parameters (corresponding
to the placebo case) in this study have been experimentally determined101 ,65,87. In
these experiments, the authors measured the bone mineral density in patients who
had one limb immobilized during convalence of a fracture. The bone mineral density
was also measured once the limb was returning to normal activity. These results
were then plotted versus time and loading history. Therefore the numerical values
identified are102 :
{
vplacebor = 2.800 week
−1 and ψplacebor = 7.5 · 10
−3
v
placebo
d = 0.805 week
−1 and ψplacebod = 3.0 · 10
−2 (2.3)
Systemic treatment
In order to numerically study the systemic effect of bisphosphonate on the peri-
implant bone evolution, three concentrations of alendronate treatment following THR
were simulated: bone remodeling with 5, 10, 20 mg systemic alendronate daily treat-
ment (ψr and vr corresponding to 5, 10, 20 mg alendronate identified values, see Table
2.1). The numerical values for the bone remodeling parameters following alendronate
treatment were obtained from a theoretical work76 based on a phase III clinical trial
of alendronate53. The parameters are applied to the whole femur.
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Table 2.1: Ratio between the remodeling parameters modified by the alendronate
presence (ψx mgr and v
x mg
r , where x=0, 5, 10, 20 mg of alendronate) and the ones
in the placebo case (ψplacebor and v
placebo
r ) used to simulate effect of oral alendronate
treatment on bone remodeling76.
Alendronate dose ψ
x mg
r
ψ
placebo
r
v
x mg
r
v
placebo
r
Placebo 1.00 1.00
5 mg 0.81 1.07
10 mg 0.75 1.17
20 mg 0.72 1.19
Drug Delivery System (DDS)
Since Zoledronate has been shown to be more efficient in inhibiting bone resorption
than alendronate, a kappa value of 0.5 is used. This value is an estimation, since
no clinical studies have been published on which an identification of the kappa value
for Zoledronate could have been performed. In order to validate the concept of
biocoating, three different sets of simulations were used. The first case called Fullcoat
1 was a simulation run with
ψx mgr
ψ
placebo
r
= ψr(κ = 0.5) =
ψr
2
The second one called Fullcoat 2 was a simulation run with
vx mgr
v
placebo
r
= vr(κ = 0.5) =
vr
2
The third one called Fullcoat 3 was a simulation run with
ψx mgr
ψ
placebo
r
= ψr(κ = 0.5) =
ψr
2
and
vx mgr
v
placebo
r
= vr(κ = 0.5) =
vr
2
.
In all three cases, any other parameter was left at the placebo value.
For the study of partial coating effect, ψr(κ = 0.5) and vr(κ = 0.5) were varied at
the same time in certain regions of the femur, as shown in Figure 2.3. The parts of
the femur that are not designated by the arrows use the standard ψr and vr values.
2.5 Finite Element Model
2.5.1 Numerical model
The three-dimensional geometry of a proximal femur was reconstructed from CT scan
slices obtained from a routine clinical examination of a 70 year old female patient.
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a) Partial 1/7
vr(κ) = vr/2
ψr(κ) = ψr/2
vr(κ) = vr/2
ψr(κ) = ψr/2
vr(κ) = vr/2
ψr(κ) = ψr/2
vr(κ) = vr/2
ψr(κ) = ψr/2
d) Partial 4
b) Partial 2/6
e) Partial 1/2/6/7
c) Partial 3/5
f) Fullcoat 3
vr(κ) = vr/2
ψr(κ) = ψr/2
vr(κ) = vr/2
ψr(κ) = ψr/2
Figure 2.3: Description of the different simulated coatings in reference to the Gruen
zones (detailed in a)) taken as pairs (1/7, 2/6, 3/5 and 4).
Use of the data was approved by the patient. The implant was numerically inserted
under supervision of an orthopedic surgeon. The initial bone density distribution cor-
responds to the density distribution obtained by the CT-scan and can be considered
as the clinical situation immediately after implant insertion. Then, a finite element
model (FEM) of the bone-implant system was obtained with a 3D mesh generator88
from the CT scan slices. The FE mesh was based on 8-node isoparametric elements
and consisted of 21’854 nodes and 8’028 elements. The implemented constitutive law
follows the linear elastic law102. At the distal end of the femur, the displacements of
the nodes were constrained. Each iteration took about 30 minutes of calculation on
a Silicon Graphics Origin 2000, using 1 out of 8 processors.
A discontinuous frictional contact between bone and implant was included, allowing
us to evaluate shear micromotion between them. The used friction law was an im-
plementation of the Coulomb’s law. The friction coefficient was 0.2. The implant’s
surface was considered as master surface and the bone’s surface as slave surface.
Every iteration corresponds to a different time step, since the “step doubling” tech-
nique is used102. The evolution equation was iteratively solved by the custom-made
software REM101 driving ABAQUS (Hibbitt, Karlsson, & Sorensen Inc., Newpark,
USA) analysis program. The forces used to simulate muscle action on the head of
the implant have been experimentally determined15 ,16,36:
• Gluteus Maximus : 1901N
• Gluteus Medius : 1237N
• Psoas : 771N
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2.5.2 Result visualisation
In order to visualize the results, the Mean Relative Density (MRD) is defined as the
sum of the densities at all the nodes of the considered part divided by the number of
nodes present in the considered part.
In order to visualize the effect of drug concentration on the micromovement at the
bone-implant interface, the Average Interface Micromovement (AIM) is defined as
the sum of the normes of the interfaces micromovements (movements between im-
plant surface and endosteal bone surface) at the bone-implant interface at all the
nodes of the interface divided by the number of nodes present in the considered part.
AIM is expressed in µm.
To visualize the spatial distribution of differences between the tested cases, a graph-
ical representation of the difference, taken node by node, of the different cases is
defined. The differences are then shown on a colour scale on the FE geometry. The
color code is : the smaller the difference the colder the colour (blue). With increasing
difference, the colour becomes warmer (red).
The MRD and AIM were reported according to the grouped Gruen zones, defined in
Figure 2.3a).
2.6 Results
2.6.1 Systemic drug delivery
The simulated effect of alendronate treatment increases the MRD by 2.5% for the 5
mg dose, 3.5% for the 10 mg dose and 4.0% for the 20 mg dose as compared to the
placebo after 60 weeks when considering all Gruen zones (Figure 2.4). At all time,
the simulated peri-implant MRD is higher with alendronate treatment compared to
placebo.
Table 2.2: MRD increases compared to placebo for each Gruen zone (in %).
Gruen zone 5 mg 10 mg 20 mg
1/7 7.0 10.4 12.0
2/6 3.2 4.3 4.9
3/5 1.0 1.4 1.6
4 0.4 0.5 0.5
The simulated systemic alendronate treatment increases the bone density in the
whole femur in a dose dependent manner when compared to the placebo case (Figure
2.5). The proximal femur (Gruen zones 1 and 7, see Table 2.2), experienced a smaller
resorption when alendronate presence is simulated than in the placebo. The zones
2/6 also experience a higher MRD but in a lesser extent. In the distal femur, the
densification is slightly increased. The increase is dose dependent but the main
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Figure 2.4: Evolution of the mean relative density (MRD) for different alendronate
doses until equilibrium (i.e. all nodes experience a stimulus which is in the equilibrium
zone) is reached (condition which stops the simulation).
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Figure 2.5: Node by node difference between the relative densities in the placebo
case and the three different alendronate doses cases. The metallic implant is shown
in grey. The code for the color code is : the smaller the difference the colder the
colour (blue). With increasing difference, the colour becomes warmer (red).
increase in MRD is between placebo and the 5 mg case, while the highest MRD is
obtained in 20 mg case. The AIM is strongly reduced in the cases where alendronate
treated bone is simulated. At equilibrium, the decrease in AIM between the placebo
and the simulated alendronate cases is 62% and only slightly dose dependent (Table
2.3). The strongest AIM decrease takes place in the proximal femur, namely the
Gruen zones 1, 2, 6 and 7 (Table 2.4). The AIM decreases in the zones 3 and 5 is
10% lower than the decreases in the zones 1, 2, 6 and 7. The AIM decrease is only
slightly dose dependent. The AIM in the Gruen zone 4 is zero because no interface
is present in this zone.
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Table 2.3: AIM for the four simulated cases.
Gruen zone Placebo 5 mg 10 mg 20 mg
AIM [µm] 110.0 41.3 41.1 41.0
Table 2.4: AIM in placebo case and alendronate cases for each Gruen zone.
Gruen zone Placebo 5 mg 10 mg 20 mg
1/7 [µm] 111.6 39.4 39.2 39.0
2/6 [µm] 108.3 38.0 37.8 37.7
3/5 [µm] 110.2 46.3 46.1 46.1
4 [µm] 0.0 0.0 0.0 0.0
2.6.2 Local drug delivery
Full coating
The three fully coated implants showed a higher MRD than the non-coated implant
(Figure 2.6). The Fullcoat 1 and Fullcoat 3 ended up with higher MRDs than the
non-coated implant, whereas Fullcoat2 reaches equilibrium with the same MRD than
the non-coated case. All three full coatings needed longer times to reach equilibrium
than the non-coated case corresponding then to a decreased rate of bone turnover.
Decreasing ψr was more effective to slow down bone resorption than decreasing vr.
For all Gruen zones and at any time, the MRD was higher in the Fullcoat 3 case
compared to the non-coated (Figure 2.7). The most marked differences were located
in zones 1 and 7 with a MRD 1.5 times higher for the Fullcoat 3 compared to the NC
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Figure 2.6: Evolution of the mean relative density for four cases being Non-coated
(NC), 50% decreased ψr (Fullcoat 1), 50% decreased vr (Fullcoat 2), 50% decreased
ψr and vr (Fullcoat 3).
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Figure 2.8: Comparison of the mean relative density evolution between local and full
biocoating.
after 50 weeks. The resorption rate φ˙ was 2.2 times higher in the non-coated case
than in the Fullcoat 3 case. When locally observing the MRD evolution (Figure 2.7),
it was noted that the largest difference between the non-coated case and Fullcoat 3
was found in the Gruen zones 1, 2, 6 and 7. The MRD of the zones 3, 4 and 5 was
slightly higher in the Fullcoat 3 case than in the non-coated case.
Partial coating
In order to demonstrate the advantage of a partial biocoating concept, one full coating
(Fullcoat3) was compared with four partially coated implants (Partial 1/7, Partial 2/6
, Partial 3/5 and Partial 1/2/6/7, see Figure 2.3). The cases Partial 1/7, Partial 2/6
and Partial 1/2/6/7 resulted in a lower MRD than Fullcoat 3 (Figure 2.8). Results
showed that the cases Partial 3/5 and Partial 4 reach almost the same equilibrium
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Figure 2.9: Spatial MRD variation of Full coating and Partial coating compared
to NC. Blue zone represents the highest difference in bone MRD while red zone
represents slight difference. The metallic implant is shown in grey and the coating
in white. The code for the color code is : the smaller the difference the colder the
colour (blue). With increasing difference, the colour becomes warmer (red).
MRD as the non-coated while the other three keep a higher MRD than the non-
coated case (data not shown). A comparison of bone MRD between Fullcoat 3 or
Partial 1/7 with the non-coated case was performed by calculating the bone MRD
difference for each node (Figure 2.9). In both coating cases, most nodes have a higher
MRD than in the non-coated case. The Partial 1/7 case reached a higher MRD in
Gruen zones 1 and 7 compared to the Fullcoat 3 case. The fully coated implant case
induced a bone slightly denser in the medial proximal bone next to the implant and
in the lateral proximal outer region of the bone. The main difference resided in the
zones 2 and 6, in particular in the lateral region next to the implant, where the bone
around the full coating case is 10% denser as in Partial 1/7. In the regions 3/5 and
4, the fully coated implant resulted also in a denser bone as compared to a partial
coating. In all cases, the denser bone was mainly located in lateral part and the
higher increases were next to the implant.
2.7 Discussion
2.7.1 Systemic drug delivery
There is a need to increase the lifespan of hip implants especially for younger patients.
For this purpose, Shanbhag et al.94 suggested the use of systemic bisphosphonate
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treatment to inhibit wear debris osteolysis. A canine total hip arthroplasty model
showed promising results. However, the use of bisphosphonate bears the danger of
side effects (throat damage, ulcer) and undesired systemic skeletal effects on bone
remodeling. Therefore, a minimal bisphosphonate dose must be used. This dose
will be a trade off between a sufficient increase of the implant stability through the
control of bone remodeling control and minimal unwanted side effects.
To evaluate the minimal dose, an existing bone remodeling model102 was further de-
veloped for the calculation of the bone density around an implant during remodeling102,74.
The model was combined with the bone remodeling parameters identified from clin-
ical studies76. This tool was used to simulate the effect of oral bisphosphonate treat-
ment on the peri-implant bone density following THR. Our model showed that all 3
alendronate doses decreased the peri-implant bone resorption but did not suppress
it, which is confirmed by results obtained by Wilkinson111 in a clinical trial with
pamidronate. The trends and the shapes of the curves representing the temporal
evolution of the bone mineral density obtained in the clinical study and with our
model are the same. By looking closer to the different zones and by adjusting the
absolute values to relative values, the effect of the bisphosphonate measured in the
clinical study111 and in our numerical study are of the same order of magnitude. The
differences between both studies could be explained by different implant geometries,
different initial bone density distribution and differences between our patient and the
patient’s femur geometry in the clinical study. The results also showed that alen-
dronate doses above 10 mg are only a little more effective than doses below 10 mg,
which is confirmed by Libermann53.
In this work, it has been assumed that alendronate treatment had no effect on the
bone formation parameters. Experimentally, it has been observed that beside resorp-
tion, formation may also decrease when bisphosphonate was used83. Nevertheless,
no evidence for reduced osteoblastic activity at individual bone formation sites was
found. Specifically, the effect of alendronate on the bone formation has not been
observed11. No adverse effects on bone structure or mineralization was seen. Alen-
dronate preserved the biomechanical properties of the bone62. Moreover the variation
of bone formation parameters (clinically and numerically) has only a limited influ-
ence on the bone remodeling around an implant since most of the peri-implant bone
is in resorption. Since the equilibrium peri-implant bone distribution is dependent
on parameters like initial bone density or type of implant, our model can be used to
optimize the dosage for a systemic alendronate treatment. Taking into account these
parameters, the goal would be to obtain the equilibrium bone density which gives
the longest possible service life of the implant with a minimal risk for the patient due
to side effects of alendronate.
One of the reasons for the failure of hip arthroplasty is osteolysis due to wear particles.
A source of the wear particles is the relative movement of the implant to the sur-
rounding bone. Moreover micromovements between the implant and the adjacent
bone would lead to the encapsulation of the implant by fibrous tissue. Therefore a
very interesting point shown by this study is that interfacial micromovements are
diminished due to bisphosphonate systemic treatment. The bisphosphonate effect
on the micromovements is not dose dependent. This is probably due to the fact
that the micromovements are only influenced by the bone very close to the implant
- 29 -
Chapter 2
surface, while the average relative bone density is influenced by the whole bone.
Systemic bisphosphonate treatment would allow the increase of the lifespan of the
implant because the alendronate treatment would partially inhibit the peri-implant
bone resorption and the micromovements at the bone-implant interface.
2.7.2 Local drug delivery
Even though, the systemic bisphosphonate treatement shows some encouraging per-
spectives to reduce the peri-implant bone resorption and to increase its service time,
another problem linked to the systemic treatement emerges. In the present case, the
drug would be distributed in the whole skeleton and not only in the bone surrounding
the implant. This is not a problem in older patients and could even be beneficial,
from the point of view of treating an age-related generalized osteoporosis. But in
young patients, the inhibition of resorption could have an adverse effect for the skel-
eton. By decreasing the resorption in a young body, the physical activity (which is
much higher than in older patients) will result in an accumulation of microcracks in
the skeleton. Since the resorption is inhibited by the systemic bisphosphonate, those
microcracks cannot be removed and result in an generalized fragilisation of the whole
skeleton. Therefore to coat the implant with the bisphosphonate to create a drug
delivery system and so counter the systemic bisphosphonate effect seemed to be a
solution. This should allow to control the bone remodeling around the implant only.
As mentionned above, the effect of bisphosphonate can be simulated by decreasing
the bone resorption parameters. The decrease of the two resorption parameters of the
model ψr and vr were effective in increasing the bone mean realtive density around
the implant. However only the variation of ψr enables maintenance of higher MRD
up to the equilibrium state. The influence of decreased vr lies mainly in delaying
bone resorption. For example, in order to decrease the MRD to a value of φ=0.65, it
took 40 weeks with a non-coated implant, 75 weeks with a decreased vr (Fullcoat 2)
while for the two cases Fullcoat 1 (ψr decreased) and Fullcoat 3 (ψr and vr decreased)
the MRD stayed always above 0.65 (Figure 2.6).
By comparing the evolution of the MRD (Figure 2.6), for the couples NC-Fullcoat 2
and Fullcoat 1-Fullcoat 3, the observed effect of a decreased vr is again to increase
the time to reach the equilibrium MRD. The consequence is that at the same moment
in the remodeling process (for example week 50), the coating inducing a decreased
vr generated a bone of higher MRD around the implant. This leads to the conclu-
sion that the ideal drug would be one that decreases ψr in order to reach a higher
equilibrium MRD and decreases vr in order to reach the equilibrium by keeping the
highest possible MRD during the remodeling process.
The distal part of the implanted femur tends to increase its MRD with time (Figure
2.7) which has been associated to the stress-shielding problem105. In the Fullcoat
as in the Partial cases, the model indicated that the distal parts of the implanted
bone (zones 3, 4 and 5) were denser than in the initial case whereas the proximal
part of the bone (zone 1, 2, 6 and 7) resorbed. This leads to a situation which is
biomechanically unfavourable to the stability of the bone-implant system110. Those
observations lead to the concept of partial biocoating. Since the densification of the
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distal zones (3, 4 and 5) is not desirable, partial coatings were simulated successively
in the zones (1, 7) and (2, 6) and (1, 2, 6 and 7). Interestingly, in all three partial
coatings, the MRD in the modified zone was higher than in the same zone for the
full biocoating. This result favoured the use of a local coating compared to a full
coating for the two reasons that first a higher bone density is obtained in the needed
regions and second no decrease of bone resorption is induced in the distal part of the
implant where an over densification already took place.
Two clinical studies related the use of implants partially coated with hydroxyapatite.
McAuley58 showed that in the case of an anatomical medullary locking hip implant,
the full coating results in less bone loss in the proximal femur but a density increase
in the distal part of the femur. But the authors admit themselves that those results
are probably particular to the design of this implant. Rosenthall86 compared the
density evolution in all Gruen regions around Multilock implants where, some were
proximally coated with hydroxyapatite while the others were not coated. They could
show that in any Gruen zone and at almost any moment, the density was higher in
the proximally coated implant. These two studies illustrate the conflicting results
that can be obtained in vivo. This fact highlights the usefulness of a numerical model
to estimate the influence of different implants on the peri-implant bone remodeling.
The model used constant values to simulate the effect of the drug. The decrease of
drug activity over time or the diffusion of drug in the bone were not accounted for.
These effects could modify the calculated bone MRD. The diffusion of the drug in
the bone will be measured in an experimental study and will be shown to be limited
(see Chapter 4). Regarding the decrease of drug activity, this effect is less important
for bisphosphonate as it has been shown that this drug is not degraded during its
stay in the body29.
2.8 Conclusion
This study shows numerically that the modification of the remodeling behaviour of
bone in patients undergoing a systemic bisphosphonate treatment allow to decrease
the peri-implant bone resorption and to decrease the micromovements at the bone-
implant interface. Therefore the evolution towards fibrous tissues at the bone-implant
interface would also be adverted8. Incorporation of drug effect in numerical studies
of bone remodeling is a promising tool especially to preclinically determine safe bi-
sphosphonate doses used in orthopedic implants in order to increase the lifespan of
the implant.
Even though the systemic use of bisphosphonate to increase the lifespan of ortho-
pedic implants is numerically shown in the first part of this work, the local use of
bisphosphonate (DDS) needs to be investigated. Therefore, the new implant concept
shows numerically its ability to modify the equilibrium bone MRD. By decreasing
the resorption parameters, a higher MRD distribution and a different bone turnover
compared to the non-coated case is observed. By using the developed model, the
effect of modifying bone remodeling parameters could be estimated which brought
useful information for specifying the targeting for future drugs used in controlling
the bone remodeling.
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Finally, the simulation of a partial biocoating resulted in a MRD distribution which
was biomechanically more favorable for a longer service time than the one obtained
for a full coating. Therefore the concept of partial biocoating could be a promising
technique to improve the service life of implants and could be particularly useful for
young patients with cementless implant. The presented model was able to take into
account the action of bone turnover-modifying drugs and to furnish suggestions for
the choice of drug which would provide the ideal peri-implant bone density distribu-
tion. The optimal control of bone remodeling in the implant surrounding could be
best achieved by a partial biocoating.
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Determination of in vitro bisphosphonate
effect on osteoblasts
3.1 Goals
The clinical use of bisphosphonate nowadays is limited to oral or intravenous use.
Therefore, the second step in developing an orthopedic implant as drug delivery
system is to determine the local drug concentrations to which osteoblasts can be
safely exposed. Even with a pharmacological treatment, wear particles will still
be generated with an orthopedic implant. It will then be important to check that
the simultaneous presence of wear particles and bisphosphonate does not lead to a
situation which would impair either the osteoblast proliferation or their ability to
differentiate.
In vitro studies quantifying the simultaneously effect of bisphosphonates and wear
particles are scarce.
The goals of this chapter are then first to determine in vitro the local concentrations
of Zoledronate which could be used without negative effect on osteoblasts prolifer-
ation and ALP activity and secondly to verify that there is no synergetic negative
effect when culturing these cells simultaneously with bisphosphonate and particles.
3.2 Flowchart
The combined effect of Zoledronate and titanium particles is studied on two cell lines
by checking their effects on proliferation and ALP activity of osteoblasts (see Figure
3.1).
3.3 Materials & Methods
3.3.1 Cell Lines
Two cell lines were used: the murine cell line MC3T3-E138 was used to study the
effect of Zoledronate and particles on the ALP expression and on the other hand,
the MG-6377 cell line was used to measure the effect of Zoledronate on human bone
cells.
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Figure 3.1: Experimental flowchart used to determine the effect of Zoledronate on
osteoblasts.
3.3.2 Cell Culture
The culture medium for MG−63 cells was composed of DMEM (Sigma−Aldrich,
St Louis, MO), 10% fetal bovine serum (Sigma−Aldrich, St Louis, MO), 1% anti-
biotic (penicillin, streptomycin) and fongicide (amphotericin B) (Invitrogen, Carls-
bad, CA). The culture medium for MC3T3−E1 cells was composed of α−MEM
(BioConcept, Allschwill, Switzerland), 2.2 g/l NaHCO3 (Sigma−Aldrich, St Louis,
MO), 0.5% essential amino acids (BioConcept, Allschwill, Switzerland), 10% FBS
(Sigma−Aldrich, St Louis, MO), 1% L−glutamine (BioWittaker, Rutherford, NJ), 50
µg/ml L−ascorbic acid (Sigma−Aldrich, St Louis, MO), 10 mM β−glycerophosphate
(Sigma−Aldrich, St Louis, MO)78 for MC3T3-E1 differentiation. EDTA (Sigma−Aldrich,
St Louis, MO) was used to control the effect of chelation on the cells and was
added at a concentration of 0.01 µM. The cells were collected by trypsinisation
(EDTA Trypsine, Invitrogen Corporation, Paisley, Unighted Kingdom) from T75
flasks, seeded at a density of 5’000 cells per well on 96 well plates, incubated at 37◦C,
5% CO2 and saturated with humidity. The MC3T3-E1 were at passage 5 and the
MG-63 at passage 93. After 24 hours, the medium was removed and replaced with
200 µl of medium containing respectively 0, 0.1, 1.0, 10.0 and 50.0 µM of Zoledron-
ate. Half of all the wells were containing titanium particles. Half of the medium was
changed every 3 days with fresh culture medium not containing any Zoledronate nor
particles. Proliferation, ALP activity and total protein were measured after 4 hours
and on days 2, 7, 14, 21 and 28. Every condition was tested in triplicates and in
three temporally separated culture series.
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3.3.3 Zoledronate
Zoledronate (1-hydroxy-2-[(1H-imidazole-1-yl)ethylidene] 1-bisphosphonic acid diso-
dium salt) was supplied by Novartis Pharmaceuticals AG (Basel, Switzerland). It
was dissolved in sterile nanopure water and freshly added to the respective culture
medium at the first medium exchange.
3.3.4 Titanium Particles
The titanium particles were purchased from Johnson Mattey company (Karlsruhe,
Germany). The distribution of particle size was performed with laser diffraction by
using Malvern MasterSizer equipment. The average particle size was 4.5 µm and
the surface area was 0.5 m2/mg. The particles, autoclaved at 135◦C for 15 minutes,
were mixed with the culture medium under sterile conditions. Using similar experi-
mental conditions, endotoxin contamination was excluded by limulus assay75. Based
on a particle weight to medium volume ratio, a concentration of 0.01% titanium
particles was prepared. One ml of particles suspension of 0.01% contained approx-
imately 60,000 particles. The titanium particule suspensions were sonicated for 30
minutes in sealed sterile container before being added to the cell culture. 0.01%
titanium particles is the threshold above which proliferation decreases and below
which proliferation is the same as control77. This concentration was used to quantify
an hypothetic synergic effect of Zoledronate and titanium particles on osteoblasts
behavior.
3.3.5 Cell proliferation
At every timepoint, the medium was completely removed by careful pipetting, and
replaced with 100 µl fresh medium. In parallel, three wells with fresh medium but
without cells were prepared and used as blank. An MTS test was performed by
adding 10 µl of CellTiter 96 Aqueous One (Promega, Madison, WI) to every well.
The resulting solution was then incubated for 1 hour at 37◦C, 5% CO2 and saturated
with humidity. 100 µl of each well were then transferred in a new 96 well plate and
the absorbance (Abs) of every well was then measured at 490 nm in a Victor plate
reader (Wallac, Turku, Finland). To calculate the proliferation, the equation (3.1)
was used. The proliferation was normalized by dividing the proliferation of every
condition at every timepoint by the proliferation of the cells exposed to neither Zole-
dronate nor particles.
Proliferation =
100 ∗ Abs(t, Zoledronate, T i)− Abs(t, Blank)
Abs(t, Zoledronate = 0, T i = 0)− Abs(t, Blank)
(3.1)
3.3.6 Cell total protein
At every timepoint, the medium was completely removed by careful pipetting. All
the wells were rinsed twice with PBS. The plates were stored at −80◦C until being
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processed. 100 µl of 1% Triton−X aq (Sigma-Aldrich, Steinheim, Germany) were
added and pipetted several times to ensure proper cell lysing. Using the Bio−Rad
protein Assay (Bio−Rad Laboratories) and complying to the manufactures indica-
tions, the total protein content was measured for every well of every condition.
The protein calibration was made using 6 dilutions in triplicate of a fetal bovine al-
bumin solution contained in the Bio−Rad Protein Assay II (Bio−Rad Laboratories,
Hercules, CA).
3.3.7 Alkaline phosphatase activity
Since MG−63 are known to produce very low amount of ALP, only the MC3T3−E1
ALP activity was measured. The cells were located on the same plates as the cells
used for the total protein assay and followed the same treatment. 100 µl p−nitrol
tablets as substrate (Sigma−Aldrich, St Louis, MO) were added. The absorbtion
was measured at 405 nm as a function of the incubation time. The ALP activity was
given by the slope of the absorption vs time curve (see Sigma, Procedure N◦245).
ALP activity was normalized by the total protein content determined as described
above.
3.3.8 Statistics
One-way ANOVA and Student’s t-test were used to determine the statistical signific-
ance of the results. A probability value of P≤0.05 was considered to be statistically
significant. The calculations were performed using the software XLSTAT 4.6 (Addin-
soft, Paris, France).
3.4 Results
3.4.1 Cell proliferation
Figure 3.2 shows the temporal evolution of proliferation of MC3T3−E1 cells exposed
to various concentrations of Zoledronate and titanium particles. It can be seen that
4 hours after the seeding, the cell proliferation is the same for all the different con-
ditions (no statistical differences). After two days, the cell proliferation is slightly
decreased for the cells treated with 0.1 and 1 µM of Zoledronate, independently of
the presence of titanium particles. The exposure of the cells to 10 and 50 µM of
Zoledronate significantly decreases the proliferation of the cells (P<0.001). After 7
days, the concentrations of 0.1 and 1 µM of Zoledronate only slightly decreased the
proliferation. When the MC3T3−E1 are exposed simultaneously to 10 µM Zoledron-
ate and titanium particles, the proliferation becomes close to the level of proliferation
measured on the cells treated with the lower doses. When 10 µM Zoledronate alone
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are present, the proliferation is decreased, but not significantly. At 50 µM Zoledro-
nate, the proliferation was completely stopped and was inhibited for all subsequent
timepoints. After 14 days, all Zoledronate treated cells, apart from the ones treated
with 50 µM, are at the same proliferation level as control. This profile stays the same
after 21 and 28 days of exposure to Zoledronate.
Figure 3.3 shows the temporal evolution of the proliferation of MG−63 cells exposed
to various concentrations of Zoledronate and titanium particles. During the first 48
hours, no difference in proliferation can be seen as a function of Zoledronate treat-
ment or titanium particle presence (no statistical differences). At 7 and 14 days,
the concentrations of 0.1 and 1 µM of Zoledronate show the same proliferation as
control. At 10 and 50 µM Zoledronate, the proliferation is, in a dose dependent
manner, strongly decreased (P<0.0001). This profile repeats itself at 21 and 28 days
of incubation.
EDTA did not show any influence on proliferation for both cell lines (data not shown).
No synergic effect of Zoledronate and particle has been quantified on osteoblasts pro-
liferation (P>0.08).
3.4.2 Alkaline phosphatase activity
Figure 3.4 shows the temporal evolution of ALP activity normalized by the total
protein content of MC3T3−E1 cells exposed to various Zoledronate concentrations
and titanium particles. In the absence of titanium particles, the ALP activity of the
cells decreased with increasing Zoledronate concentration (P<0.0001). Even though,
two behaviors can be noticed. First, the control cells, the cells treated with 0.1, 1
µM Zoledronate and the cells treated with EDTA show an increase in ALP activity
as compared to day 0 that culminates after 7 days before decreasing and levelling
off until day 28. Second, the cells treated with 10 and 50 µM Zoledronate showed a
small increase after 48 hours of incubation before decreasing to low levels until day
28. In a dose-dependent manner, the maximum ALP activity decreases from 0.274 to
0.114 nM PNP/min/mg protein when the cells were exposed to no Zoledronate and
1 µM Zoledronate respectively. When MC3T3−E1 cells were exposed to titanium
particles, the evolution of ALP activity with time and Zoledronate concentration was
very close to the evolution when no particles are present, apart from the maxium val-
ues which were 2 to 5 times lower than when the particles were absent (P<0.0001).
The largest decrease in ALP activity when adding particles was for the control case.
The maximum ALP activity is 0.060 nM PNP/min/mg protein. No synergic effect of
Zoledronate and particle has been quantified on ALP activity (P<0.005). Figure 3.5
shows the same data as in Figure 3.4 but in a different perspective. When observed
along the chronological line, the key timepoints are 2, 7 and 14 days. Day 0 shows
no difference in ALP activity independently of the titanium particles concentration
or the Zoledronate concentration. The ALP activity evolution as a function of Zole-
dronate concentration or particles presence at timepoints 21 and 28 are very close to
the ALP activity at day 14.
At day 2, when Ti particles are present no statistically significant difference can be
seen in ALP activity as a function of Zoledronate concentration. When no particles
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Figure 3.2: Proliferation of MC3T3−E1 cells over time exposed to Zoledronate con-
centration of 0, 0.1, 1.0, 10.0 and 50.0µM, with and without particles (n=3, mean ±
sem).
- 39 -
Chapter 3
0.00% Ti
0.01% Ti
Zoledronate Concentration [µM]
P
ro
lif
e
ra
ti
o
n
 [
%
]
10 10010.10
120
100
80
60
40
20
(a) Day 0
0.00% Ti
0.01% Ti
Zoledronate Concentration [µM]
P
ro
lif
e
ra
ti
o
n
 [
%
]
10 10010.10
120
100
80
60
40
20
(b) Day 2
0.00% Ti
0.01% Ti
Zoledronate Concentration [µM]
P
ro
lif
e
ra
ti
o
n
 [
%
]
10 10010.10
120
100
80
60
40
20
(c) Day 7
0.00% Ti
0.01% Ti
Zoledronate Concentration [µM]
P
ro
lif
e
ra
ti
o
n
 [
%
]
10 10010.10
120
100
80
60
40
20
(d) Day 14
0.00% Ti
0.01% Ti
Zoledronate Concentration [µM]
P
ro
lif
e
ra
ti
o
n
 [
%
]
10 10010.10
120
100
80
60
40
20
(e) Day 21
Zoledronate Concentration [µM]
P
ro
lif
e
ra
ti
o
n
 [
%
]
10 10010.10
120
100
80
60
40
20
0.00% Ti
0.01% Ti
(f) Day 28
Figure 3.3: Proliferation of MG−63 cells over time exposed to Zoledronate concen-
tration of 0, 0.1, 1.0, 10.0 and 50.0µM, with and without particles (n=3, mean ±
sem).
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Figure 3.4: Normalized ALP activity of MC3T3-E1 over time and Zoledronate con-
centration of 0, 0.1, 1.0, 10.0 and 50.0 µM (n=3, mean ± sem), a) without titanium
particles, b) with titanium particles.
- 41 -
Chapter 3
are present, an increase in ALP activity vs control can be observed when the osteo-
blasts are treated with 10 and 50 µM. But only the increase at the highest Zoledronate
concentration is statistically significant (P<0.02).
At day 7, when particles are present, the osteoblasts treated with 0, 0.1, 1 µM and
EDTA are at the same level. The 10 and 50 µM treatement significantly decrease the
ALP activity. When no particles are present, the ALP activity decreases logarithmit-
ically with the Zoledronate concentrations up to 10 µM. Only the difference between
0 and 1 µM is statistically different (P<0.05). The ALP activity of the osteoblasts
cells treated with EDTA or with 1 µM is the same (P=0.99). The activity at 10 µM
is the same as when the cells are treated with 50 µM.
At Day 14, there is no statistical difference between the cells exposed to titanium and
those which are not, independently of the Zoledronate content. The ALP activity of
the cells treated with 10 or 50 µM are significantly lower (P<0.05).
3.5 Discussion
This study was performed to determine in vitro to which Zoledronate concentration
osteoblasts can be exposed and to quantify the possible synergetic effect of wear
particles and Zoledronate on osteoblasts proliferation and differentiation. This in-
formation is important in the perspective of developing an orthopedic implant as
drug delivery system. Few studies have been performed to determine in vitro the ef-
fect of Zoledronate on osteoblast behavior, while virtually no information is available
when bisphosphonate and wear particles are simultaneously present.
The effect of Zoledronate on osteoblast proliferation was dependent on its concentra-
tion with a clear cutoff concentration below which the proliferation is the same as in
the control group, whereas above the cutoff concentration, the proliferation is close
to zero. The proliferation of osteoblasts treated with Zoledronate follows the same
profile shown using other bisphosphonates81 ,108,35. This observation is valid for both
cell lines used, human and murine.
Two differences were observed between the effect of Zoledronate on human and mur-
ine osteoblasts. The first difference is the cutoff concentration which is 10 µM for
murine osteoblasts while for human osteoblasts the value is 1 µM. This different
sensitivity to bisphosphonate concentration has already been observed between mice
and human with alendronate treatment114. Another explanation of this difference
could be found in cell type, since the MG-63 are cells issued from human osteosar-
coma, while MC3T3-E1 is a non-transformed cell line. Therefore MG-63 could be
more sensitive to Zoledronate, since it has been shown to be effective in treating
osteosarcoma97. The cutoff Zoledronate concentration on human osteoblasts prolif-
eration was comparable to the value obtained in a previous study81. The second
difference is the temporal behavior at 10 µM. For human osteoblasts, the prolifera-
tion decreases after 7 days and stays at a low level. In contrary, the proliferation of
murine osteoblasts exposed to 10 µM Zoledronate decreased from day 2 on, but then
recovered starting from day 7 on to reach control level at day 14. One explanation
of this recovery effect could be that proliferation is not suppressed in the murine
osteoblast but only slowed down. Advancing in time, more and more osteoblasts
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Figure 3.5: Normalized ALP activity of MC3T3−E1 cells over time exposed to Zole-
dronate concentration of 0, 0.1, 1.0, 10.0 and 50.0 µM, with and without particles
(n=3, mean ± sem).
would be mitogenically created. This would lead to lower quantity of Zoledronate
per osteoblast allowing to cross the cutoff concentration. The observation that Zole-
dronate slowed down the proliferation would also explain the fact that osteoblasts
exposed to 50 µM were round but did not detach over time. This could be suppor-
ted by the fact that Zoledronate accelerates osteoblast differentiation via inhibition
of the mevalonate pathway82 resulting in an earlier mineralization process than in
control. Inhibition of hFOB cell proliferation by Zoledronate was partially reversed
by mevalonate pathway intermediates, and stimulation of hFOB cell mineralization
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was completely reversed by mevalonate pathway intermediates81.
As shown by Farley28, the ALP activity of osteoblasts is inversely proportional to
the amount of calcium in the medium. Since Zoledronate is known for its ability to
precipitate divalent metallic ions like calcium, the concentration of medium calcium
is decreasing with increasing Zoledronate concentration. This certainly explains the
decreasing ALP activity with increasing Zoledronate observed in the present study.
Moreover, this observation is supported by the result that EDTA treatment, a known
chelator, induced a similarly decreased ALP activity. However, in vivo this decreased
calcium concentration in the presence of Zoledronate would probably be counterbal-
anced by the calcium homeostasis.
In previous studies, the effect of particles has been shown with widespread results,
but mostly showing that the presence of particles stimulated bone resorption37,98,94
and inhibited bone formation115,107,118,76. Using a previously determined titanium
particle concentration, similar proliferation results with MG−63 cells were obtained
as presented in another study77.
The lowered ALP activity due to particle presence was significantly stronger than
the decrease due to Zoledronate. Lohmann55 suggested that the presence of particles
does push the osteoblasts either to produce cells that are less differentiated or to slow
down protein synthesis in general. They showed also that most of the phagocytosed
particles are located in parts of the cells involved in protein assembling and packaging
and not in the nucleus. This is supported by the fact that we did not find any effects
of the particles on the quantities of mRNA isolated from MC3T3−E1 cells (data not
shown). Rodrigo84 concluded that post−transcriptional events are influenced by the
presence of particles.
As mentioned in Chapter 1, we found only one study describing the simultaneous
effect of bisphophonates and particles. Hyvonen41 studied the in vivo effect of clo-
dronate treated hydroxyapatite particles on the phagocytic activity of peritoneal rat
macrophages. This study showed that the phagocytic activity of macrophages is re-
duced by the presence of clodronate after only 48 hours. The hydroxyapatite particles
were used as bisphosphonate carrier and did not result from a wear process.
In the present study, the culture of osteoblasts with Zoledronate and titanium particles
did neither create a positive nor a negative synergy on osteoblasts behavior. Clearly
we showed that the presence of titanium particles decreases the osteoblasts ALP
activity more than Zoledronate at all Zoledronate concentrations. This means, in
the limitations of the present in vitro study, that in the case of a Zoledronate loaded
coating or with systemic Zoledronate treatment following a total hip arthroplasty,
the presence of Zoledronate at concentration lower than 1 µM would not decrease
the proliferation or affect the differentiation of osteoblasts.
3.6 Conclusion
We showed that Zoledronate decreases proliferation at concentration above 10 µM
for MC3T3−E1 cells and above 1 µM for MG−63 cells. The presence of titanium
particles almost completely suppressed ALP activity, while Zoledronate influenced
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the ALP activity in the absence of particles, probably through the chelation of cal-
cium. Importantly, no synergetic effect of Zoledronate and titanium particles was
observed on osteoblasts.
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Diffusion of bisphosphonate in bone
4.1 Goals
The goal of the present chapter was to study how the Zoledronate will diffuse when
it is in contact with endosteal bone and if the drug will be completly retained by the
bone or if it will leave it.
4.2 Flowchart
In the studied drug delivery system, the Zoledronate is in direct contact with the
endosteal bone (Figure 4.1). Different questions need to be clarified : how much
Zoledronate will enter the bone? How fast and how far does the Zoledronate diffuse
in bone? How much Zoledronate will leave the bone by diffusing through the peri-
osteum? In order to answer those questions, the experimental pathway schematized
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Figure 4.1: Schematic view of the implant (on the left), coated with the hydroxyapat-
ite and Zoledronate (in the middle), in contact with the endosteal bone (on the right).
In the bone, different species are in contact with the implant: chemical species (like
calcium) will interact with the bisphosphonate and biological species (like osteoclasts
and osteoblasts) will be influenced by the presence of Zoledronate.
in Figure 4.2 was developped. The endosteal side of bone slices obtained from a
femoral head were exposed to radioactively labelled Zoledronate. The Zoledronate
concentration was then measured in the bone slice using autoradiography and in both
solutions (endosteal and periosteal) using scintillation.
4.3 Materials & Methods
The Zoledronate concentration and location was measured with two methods :
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Figure 4.2: Experimental flowchart used to determine the diffusion of Zoledronate in
bone.
• Autoradiography is used to quantify the Zoledronate concentration and location
in the solid bone,
• Scintillation is used to quantify the Zoledronate concentration in the liquids
recorevered from the experiment.
4.3.1 Sample preparation
The bone slices where obtained from the femur’s head of a 33 years old female
patient who underwent THR at the Hoˆpital Orthope´dique de la Suisse Romande
in accordance with the Ethic Comittee of University Hospital in Lausanne (Ethical
Protocol 51/02). The slices were cut using a diamond-thread saw Well3242 (Well
Walter Ebner, Le Locle, Switzerland). The bone slices were 550 µm thick and 1cm
wide and composed of trabecular bone (Figure 4.3).
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Figure 4.3: The cutting procedure set up to obtain human bone slices of controlled
thickness starts with the sawing of a bone slice from the femoral head using a pneu-
matic saw Synthes8010 (Synthes, Switzerland). A bone cube is obtained by cutting
along the endosteal-periosteal axis. The bone cube is then sliced in 550 µm thick
slices using a diamond thread saw.
4.3.2 Diffusion quantification
The bone slice is inserted into a plexiglas cell (Figure 4.4(a)). This cell is made out
of 2 plexiglas parts : a container and a cover. A 600 µm thick silicon rubber seal
is placed on the bottom of the container. The seal runs along the sides of the bone
slice, isolating the endosteal bone from the periosteal side, leaving no other diffusion
pathway than the one through the bone. The cover is then imbricated into the con-
tainer. A metallic frame is set around the closed plexiglas cell and four screws are
tighten to compress the seal (now located between cover and container bottom) to
achieve air tightness. The air thightness is checked by applying an air pressure on
the endosteal side using a seringue at injection point A. The cell was air-tight when
the piston of another seringue at injection point B did not move.
The Zoledronate solution concentration is set to 25 µM in order to have a strong
signal. The Zoledronate is marked with C14 and is kindly provided by Dr J. Green
(Novartis Pharmaceuticals AG, Basel, Switzerland). The molecular weight of Zoled-
ronate is 280 Da.
On the endosteal side (injection point A), the Zoledronate solution was bubble-free
inserted, while on the periosteal side (injection point B), PBS was bubble-free injec-
ted. The setup was then let for diffusion for 1 day, 7 days and 30 days. Once the
experiment duration was over, both solutions were removed and stored at -80◦C for
later scintillation analysis. Every experiment duration was repeated in triplicates.
The diffusion setup was tested by diffusing tetramethylrhodamine TMR (Moleculare
Probes Europe, Leiden , The Netherlands) through bone. TMR is a synthetic fluor-
escent dye and has a molecular weight of 430 Da which is close to the molecular
weight of Zoledronate. Its excitation range is between 520 and 550 nm, its emission
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Figure 4.4: Setup for bone diffusion experiment. a) 3D view of the setup. The bone
slice is shown in grey with the silicon seal running around it, b) Top view of the bone
slice mounted in the diffusion cell.
peak is at 580 nm. TMR is excited by the spectral line of 543 nm of a green HE-Ne
laser mounted of the confocal fluorescence microscope. Fluorescence light is detected
by the microscope with the help of a longpass filter for wavelength ≤ 570 nm. The
microscope is connected to a computer allowing the visualisation and digitalization
of the images. The injection procedure of TMR is the same as the one used for Zole-
dronate. The initial concentration is 5 mM and the experiment duration is set to 48
and 72 hours. The samples are taken from bovine bone and were prepared similarly
to the human bone samples. The fluorescence experiment with TMR showed that
the experimental setup was functionning. The TMR molecule diffused through the
bone while no dye flowed around the bone (Figure 4.5). Therefore this diffusion cell
design can be used to measure the diffusion of radioactive Zoledronate through bone.
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Figure 4.5: Rhodamine diffusion in bonvine bone. In order to test the diffusion cell
setup, test runs with bovine bone and rhodamine. The diffusion front moves accross
the bone with a steady rate of 1 mm/day. The peak of rhodamine in the most
periosteal region is also observed.
TMR was used instead of Zoledronate, because TMR is fluorescent and therefore
easier to detect than the radioactive Zoledronate.
4.3.3 Scintillation
A solution of 0.6 ml of Optiphase Hisafe 2 (PerkinElmer, Torrance, USA) are mixed
with 0.2 ml of the endosteal or periosteal liquid samples. The obtained mixture is
then inserted into the scintillation counter TRIATHLER (Hidex, Turku, Finland). A
scintillation liquid is composed of an aromatic component and a fluorescent molecule.
The particles emitted due to the radioactive decay of the marked sample excite the
aromatic molecule. These excited electrons will then be transferred to the fluores-
cent molecule which will therefore emit light. The scintillation counter then counts
the number of emitted photons which is proportional to the quantity of radioactive
material.
In order to calibrate the scintillation experiment, a 25 µM C14-Zoledronate solution
was diluted 8 times by a twofold, thus obtaining 9 solutions ranging from 25 µM
to 0.097 µM. One pure water solution was used as 0 µM solution. Every Zoledro-
nate content was measured in triplicate. The scintillation counts were fitted with
the C14-Zoledronate concentrations using a linear function. The linear correlation
is very strong (R2=0.99 ; Figure 4.6) and will be used to calculate the Zoledronate
concentrations of the endosteal and periosteal solutions obtained from the diffusion
experiments. The detection limit is 0.01 µM.
4.3.4 Radiography analysis
After each experiment, the bone slice was stored at -80◦C to stop the diffusion process.
Once all the experiments were performed, the bone samples were disposed in an
exposure box, where an autoradiography paper X-Omat AR Film (Kodak, Chalon-
sur-Saone, France) was exposed to the bone samples at -20◦C. The exposure time
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Figure 4.6: Scintillation calibration. To determine the Zoledronate concentration in
solution, it was necessary to determine the relationship between scintillation count
numbers and the Zoledronate concentration (mean ± sem, n=3).
is set to 24 hours, after which the autoradiographic paper is inserted into diverse
revealing baths Curix 60 (AGFA, Gera, Germany). The resulting pictures are scanned
(SnapTouch, AGFA, Gera, Germany) at a resolution of 300 dpi with the endosteal
side on the left. The pictures were analyzed with the software imageJ (National
Institue of Health, USA) where the average gray level of every column of the picture
pixel’s is calculated and plotted against the distance along the endosteal-periosteal
axis.
Four distances were selected for the statistical analysis : 0, 2, 6 and 9 mm from the
endosteal side of the sample.
The relative cumulated Zoledronate concentration is calculated by adding up all
the previous Zoledronate concentrations while moving along the endosteal-periosteal
axis dividing by the total summed concentrations of Zoledronate in the scanned bone
slice. This variable is calculated to determine the percentage of the total Zoledronate
present in the bone between the endosteal side and the point shown on the distance
axis.
4.3.5 Statistics
One-way ANOVA and Student’s t-test were used to determine the statistical signi-
ficance of the results. The analyzed factors are the position along the endosteal-
periosteal direction and the experiment duration. A probability value of P≤0.05 was
considered to be statistically significant. The calculations were performed using the
software XLSTAT 4.6 (Addinsoft, Paris, France).
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4.4 Results
Three typical autoradiographies obtained after diffusion of C14 Zoledronate during 1
day, 7 days and 30 days are shown on Figure 4.7. After 1 day of diffusion, most of the
Zoledronate is concentrated in the two first millimeters of the bone (Figure 4.7(a)).
This situation does not greatly change after 7 days (Figure 4.7(b)). After 30 days of
diffusion, the Zoledronate has moved towards the periosteal bone and reaches now
2.5 mm into the bone from the endosteal bone (Figure 4.7(c)). The Zoledronate dis-
tribution is radially not uniform: probably the drug uses the intratrabecular cavities
to enter the bone as observed in the epifluorescence results.
The curves obtained from the autoradiography of the bone samples, through which
radioactive Zoledronate has diffused, show mainly three features (Figure 4.8). The
first one is a strong peak located on the endosteal bone and extending over a dis-
tance of around 2.5 mm. The second feature is a plateau that ranges through the
rest of the bone up to the periosteum. The third feature is a peak located towards
the periosteal side where the Zoledronate content increases before decreasing to zero.
The Zoledronate concentration distribution is almost the same between day 1 and
day 7, apart that the plateau (located between 4 mm and 8 mm) is slightly higher
after 7 days. This trend is confirmed after 30 days. Moreover, the endosteal peak
concentration seems to broaden with time. Four distances were selected for the stat-
1 mm
E P
(a) 1 Day
1 mm
E P
(b) 7 days
1 mm
E P
(c) 30 days
Figure 4.7: Autoradiographies of bone samples after Zoledronate diffusion for 1 day,
7 days and 30 days (E=endosteal side of the bone, P=periosteal side of the bone).
The black zones are containing Zoledronate.
istical analysis : 0, 2, 7 and 9 mm from the endosteal side of the sample. Every
point has been selected for its particular position in the concentration curves. The
0 mm mark locates the most endosteal part of the bone and is in direct contact
with the Zoledronate solution. Two millimeter is the distance at which the slope of
the concentration curve changes. The 7 mm point locates a point reprensentative of
the plateau reached towards the middle of the sample. The 9 mm limit is the most
periosteal side of the bone samples (see Figure 4.8).
All four selected points were statistically different from each other at every timepoint
(P≤0.01). At 0, 2, 7 and 9 mm the difference in Zoledronate concentration measured,
was statistically not different between the three experiment durations at any point
of the curve (Figure 4.9).
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Figure 4.8: Zoledronate distribution in bone. Image analysis of the autoradiographies
of the bone through which Zoledronate has diffused.
The cumulated Zoledronate concentration has been calculated for the three ex-
periment durations (Figure 4.10). All three curves follow the same pattern : first
a steep increase of the Zoledronate cumulative concentration up to 2 mm into the
bone, followed by a slow increase up to the periosteal part of the bone. The curves
for the experiment durations of 1 day and 30 days are parallel in the first millimeter
of bone. Between 1 mm and 2.5 mm, the curve for the experiment duration of 7
days follows an intermediate path. It can be noticed that for the first 0.5 mm the
7 days curve is equal to the 30 days curve (Figure 4.10, rectangle A). From 0.5 mm
to 2.5 mm the curve for the 7 days experiment duration is between the 1 day and
30 days curve. From 2.5 mm up to the periosteal side, the 7 days curve is very close
to the 1 day curve (Figure 4.10, rectangle B). The Zoledronate concentration in the
endosteal liquid decreases with time and reaches a value corresponding to 20% of the
initial Zoledronate concentration (Figure 4.11). The concentration of Zoledronate in
the periosteal liquid was below the detection limit.
4.5 Discussion
The goal of this chapter is to verify that Zoledronate stays in the peri-implant bone
and that the bisphosphonate does not leave the bone. Moreover the experiments
are designed to quantify the concentration profile of Zoledronate in the bone. The
distribution of Zoledronate in the bone is of interest since the osteoclasts and the
osteoblasts activity is dependent on the Zoledronate concentration. Even though the
results show that the Zoledronate leaves the endosteal solution to enter the bone
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Figure 4.9: Four points along the endosteal-periosteal axis were selected for statistical
analysis. Two variables were calculated for those points and statistical analysis was
performed : a) the average Zoledronate concentration and b) relative cumulated
Zoledronate concentration (mean ± sem, n=3).
(Figure 4.11), the measurement of the Zoledronate concentration in the periosteal
solution shows the complete absence of Zoledronate. Therefore, the conclusion can be
drawn that, in the limitations of the experiment, Zoledronate will enter the bone by
diffusion phenomena but not leave it. By measuring the residual Zoledronate content
in the endosteal solution, it can be seen that the major part of the Zoledronate enters
the bone during the first 7 days of diffusion. The drug then accumulates in the first
2 mm and therefore stays in the endosteal bone. It is interesting to note that during
the first 7 days of diffusion the Zoledronate concentration in the endosteal solution
decreases while it increases at the endosteal part of the bone. In opposition to this
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Figure 4.10: The cumulative Zoledronate concentration is presented for 1, 7 and 30
days. This graph allows to see how much Zoledronate is accumulated in the bone as
a function of the distance to the endosteal bone (mean ± SEM, n=3).
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Figure 4.11: Zoledronate concentration in the endosteal liquid (mean ± sem, n=3).
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fact, the Zoledronate concentration in the endosteal bone does not increase in the
following 23 days but the Zoledronate concentration still decreases in the solution.
This effect can be explained by the observation that the Zoledronate concentration
on the plateau (2 mm to 9 mm) increases during the last 23 days of the experiment.
Moreover, Zoledronate seems to accumulate in the periosteal part of the bone slice.
This can be either due to the fact that Zoledronate cannot leave the bone (which is
shown by the absence of Zoledronate in the periosteal solution even after a 30 days
of diffusion) or to a change in the bone structure between the bone present in the
first 9 mm and the bone in the periosteal region. Probably it is a combination of
both factors.
The Zoledronate concentration profile does almost not change during the 30 days
of the experiment. When comparing the cumulated Zoledronate content and the
residual Zoledronate concentration, a certain discrepancy appears. The scintillation
experiment shows a 3 times lower Zoledronate concentration in the endosteal solution
after 30 days of diffusion than after 1 day of diffusion. In opposition, the cumulated
Zoledronate concentration in the bone measured by autoradiography shows only a
1.3 times higher content after 30 days than after 1 day. The discrepancy is probably
due to higher accuracy of the scintillation method as compared to the autoradio-
graphic method. To confirm this hypothesis, it was tried to shread the bone and
to measure the Zoledronate content by scintillation. The obtained results were very
instable. This instability could be linked to the shreading method. So this approach
was abondonned and the autoradiography method was kept since it gave enough in-
formation of how the Zoledronate is distributed in the bone.
Knothe48, 47 showed that a mechanical load applied to a bone can increase the dif-
fusion rate of molecules through the lacunocanalicular system. The effect of the
mechanical load on the molecular diffusion in bone is also dependent on the size of
the molecule, the effect being higher on larger molecules. In our experiment, the
pressure parameter may be less important since Zoledronate strongly binds to bone
mineral. Zoledronate is even smaller than the smallest tracer Knothe used. Therefore
the mechanical load should have a small effect on the obtained results.
In the presented experiments, the Zoledronate was in solution and not contained in
a coating. This choice is justified by the fact that the facility used to impregnate the
coated implant could not accept radioactive material (due to legislation). Moreover,
when the HA coating is present in the body, it dissolves which would also place the
Zoledronate in a solution in contact with bone.
The experiment duration is much shorter than the expected lifetime of an implant.
Choosing longer experiment duration to study long-term behaviour of this system
would have made no real clinical sense. This is mainly due to the absence of bio-
logical activity of our sample. Another possible extent of these experiments would
have been to use bone from different patients.
4.6 Conclusion
One of the main problems with the systemic treatment in young patients is that
the Zoledronate will be found in the whole skeleton and not only in the region of
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interest, i.e. the peri-implant bone. The use of the implant as a drug delivery system
is studied to establish that the bisphosphonate will stay in the peri-implant bone.
In the limitation of these diffusion experiments, the Zoledronate left the endosteal
solution, entered the bone and stayed in the peri-implant bone. This is an important
positive result for the drug delivery system. The major part of the Zoledronate was
absorbed in the first 7 days of diffusion. It could also be shown that the Zoledronate
did not leave the bone in the tested conditions. Taken all together, the results show
that the Zoledronate enters quickly and stays in the bone, more precisely in the
endosteal bone. Therefore the use of Zoledronate in a drug delivering implant is
potentially interesting. Finally, the data obtained in the in vitro (chapter 3) and in
the diffusion experiments (chapter 4) were used to plan an animal study to determine
the effect of Zoledronate containing HA on the bone in living rats.
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In vivo study of DDS for bisphosphonate
5.1 Goals
The goal of this study is to determine whether Zoledronate locally released from
an HA coated implant could increase the mechanical fixation of metallic implant
in bones. Therefore the study uses a Zoledronate concentration range to determ-
ine which concentration leads to the optimal bone density distribution around the
implant. We define the optimal distribution as the distribution that leads to the
highest mechanical stability of the implant as determined by the maximal pullout
force. Moreover the changes in the bone structure are also assessed using histo-
morphometric measurements.
5.2 Flowchart
The following path was followed : Half of the specimens were used for destructive
density and histomorphometric measurement using an SEM while the other half of the
specimens was used for non-destructive density and histomorphometric measurement
using µ-CT. The latest set of specimens was finally used for destructive pullout
testing. Image analysis allows to obtain bone density as function of the distance to
the implant. The histomorphometric parameters are calculated as function of the
Zoledronate content of the coating.
5.3 Materials & Methods
5.3.1 Animals
45 female 6 months-old Wistar rats were used for this experiment. The animals had
free access to normal diet. The animals were randomly separated in five groups rep-
resenting the different Zoledronate concentrations in the HA coating : 0, 0.2, 2.1, 8.5
and 16 µg/implant.
25 rats were ovariectomized 6 weeks before the implantation in order to induce os-
teoporosis. For convenience, these rats will be referred to as OVX rats. 20 rats
were kept non-ovariectomized and will be referred to as normal rats. The column
entitled ”Rats” in Table 5.1 and Table 5.2 shows the number of rats implanted for
this study. Six rats died of causes unrelated to the study. Each rat received two im-
plants containing the same Zoledronate concentration, one in each condyle. For each
animal, one condyle was used for density measurement and histomorphometric meas-
urements while the contralateral condyle was used for µ-CT and pullout test. The
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Figure 5.1: Schematic view of the use of the different condyles implanted during 3
weeks. Half of the samples have been sliced and SEM analysis of the bone density was
performed. The other half has been used for µ-CT measurement before the pullout
testing.
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Table 5.1: Number of normal rats per Zoledronate concentration and femurs (slices)
per histomorphometry and pullout
Zoledronate concentration Rats Histomorphometry Pullout
Control 4 3 (18) 2
0.2 µg/implant 4 2 (28) 1
2.1 µg/implant 4 4 (32) 3
8.5 µg/implant 4 4 (33) 4
16 µg/implant 4 4 (21) 3
Table 5.2: Number of OVX rats per Zoledronate concentration and femurs (slices)
per histomorphometry and pullout
Zoledronate concentrations Rats Histomorphometry Pullout
Control 5 5 (40) 4
0.2 µg/implant 5 5 (35) 4
2.1 µg/implant 5 3 (27) 3
8.5 µg/implant 5 5 (42) 4
16 µg/implant 5 4 (39) 4
column ”Histomorphometry” gives the number of femurs used for the density and
histomorphometry measurements. In parenthesis the total number of slides obtained
is given. The column ”Pullout” gives the number of condyles tested for every Zoled-
ronate concentration. Some femurs could not be used for pullout testing because the
condyle was damaged during tissue removal.
5.3.2 Metal implants and Zoledronate
Titanium alloy (TA6V) hollow cylinders (diameter: 3 mm ; length: 5 mm) were
plasma coated with hydroxyapatite (thickness : 20 µm ; crystallinity index 62%).
Zoledronate (1-hydroxy-2-[(1H-imidazole-1-yl)ethylidene] 1-bisphosphonic acid diso-
dium salt) was supplied by Novartis Pharmaceuticals AG (Basel, Switzerland).
5.3.3 Grafting of Zoledronate
The chemical association of Zoledronate with the HA coating was carried out by
soaking the implants in a aqueous Zoledronate solution. No stirring of the reaction
vessel was performed to prevent any mechanical erosion of the HA coating. Typically,
19 implants were immersed for 48 hours in 5 ml of aqueous Zoledronate solutions of
variable concentration: 2.25 10−6, 2.25 10−5, 2.25 10−4 and 2.25 10−3 mol l−1, leading
to loaded coatings. Then, the remaining amount of Zoledronate in the supernatant
at the end of the reaction was determined as previously described44, using a protocol
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based on the Ames method2 for the determination of the phosphorus content in solu-
tion. By difference with the initial amount of Zoledronate present in solution, the
Zoledronate-loading onto the implants was deduced, namely 1.9-2.1 µg Zoledronate
per implant (corresponding to a full incorporation of Zoledronate), 8-9 µg Zoledro-
nate per implant (corresponding to a 35 % incorporation ratio), 16 µg Zoledronate
per implant (corresponding to a 7 % incorporation ratio). All the Zoledronate-
association experiments were repeated twice, leading to reproducible results. Due
to the detection limit of the method, the Zoledronate-loading for the lowest grafting
concentration could not be measured. Taking into account the data described above
however, it is reasonable to assume that Zoledronate was quantitatively incorporated,
with a value of 0.2 µg per implant.
5.3.4 Surgical protocol
The protocol for the animal experiment was approved by the local Ethical Comittee
for Animal studies of the National Veterinary School of Nantes. Animals were kept at
the Experimental Surgery Laboratory of the Nantes University of Medicine according
to European Community guidelines for the care and use of laboratory animals (DE
86/609/CEE).
Beforehand the implants were autoclaved for sterilization. Surgical procedures were
conducted under general anesthesia using intra-peritoneal injection of sodium thi-
opental associated with sub-cutaneous injection of morphine sulfate. Bilateral im-
plantations were performed at the distal end of the femurs, at the epiphyso-metaphyseal
junction.
The surgical implantation was performed by a senior veterinarian (Prof. O. Gauth-
ier, Surgery and Anesthesia group, National Veterinarian School, Nantes, France).
After lateral arthrotomy of the knee joint, the lateral condyle was exposed and drilled
perpendicularly to the long axis of the femur. The drilling procedure was performed
with two successive bits (2.2 mm and 2.8 mm in diameter) on a low-speed rotative
dental hand piece and under sterile saline irrigation. Hemostasis of the bone cavity
was controlled with sterile gauges and the coated implant was then gently inserted
into the cavity under digital pressure. Articular and cutaneous tissues were closed in
two separate layers. After surgery, all the animals returned to a normal activity.
Animals were killed 3 weeks after implantation by intracardiac injection of overdosed
sodium pentobarbital, after induction of intraperitoneal general anesthesia.
5.3.5 Sample preparation for SEM
The femoral ends of 39 femurs were immediately dissected from the animals, fixed in
glutaraldehyde solution and stored in a 4% paraformaldhehyde, 0.1% glutaraldehyde
in 0.08 M cacodylate buffer.
Using a hand piece, the condyle was sawed off 1 cm above the implant. The sample
was dehydrated in a serie of alcohol solutions. The first impregnation step was
to soak the sample in a mixture of 50% alcohol 100◦ and 50% metyl-methacrylate
MMA (Fluka Chemika, Sigma Aldrich Chemie Gmbh, Steinheim, Germany) during
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8.5 hours. The second impregnation step was to soak the sample in pure MMA
during 8.5 hours.
The first inclusion step was to soak the dehydrated sample during 2 hours under
vacuum in a solution containing 90% MMA, 10% dibutylphtalate (Fluka Chemika,
Sigma Aldrich Chemie Gmbh, Steinheim, Germany) and 1% benzoyl peroxyde (Fluka
Chemika, Sigma Aldrich Chemie Gmbh, Steinheim, Germany). The sample was
then removed from the solution and soaked in the same solution but enhanced by a
polymerisation activator (N,N dimethyl-p-toluidine) (Fluka Chemika, Sigma Aldrich
Chemie Gmbh, Steinheim, Germany). The polymerisation took place at –20◦C and
was complete after 48 hours.
The samples were cut in slices 100 µm thick using a Microtome saw 1600 (Leica,
Nussloch, Germany). The cutting plane was perpendicular to the rotation axis of
the implant.
5.3.6 SEM
The slices were carbon plated. The samples were then observed in an JEOL JSM
6300 scanning electron microscope (JEOL, Peabody, USA) using the backscattered
electron detector allowing to distinguish mineralized bone from soft tissue. Each
sample was observed at two different magnifications : 10x and 23x. These two
magnifications were chosen to assess the influence of Zoledronate close to the implant
and further away.
Using Quantimet (Zeiss, Jena, Germany), the bone density and bone surface was
measured as a function of the distance from the surface of the coated implant up to
a distance of 200 µm. The bone density is defined as the ratio of the white surface
of the examined area divided by the total surface of the examined area. All the
distances are given relatively to the external surface of the coating deposited on the
implant.
5.3.7 Histomorphometry
Some studies106 have shown a connection between mechanical properties and the
bone structure. Therefore a set of histomorphometric parameters were calculated.
Only the ones influenced by the Zoledronate presence are shown. The following histo-
morphometric parameters were measured : mean length of free-to-free end branches
(FFS), mean length of node-to-free end branches (NFS), node to free end ratio (NF),
mean length of node to node struts (NNS), number of free ends in the calcified skel-
eton (FEC), skeleton length.
The calculations were performed using a homewritten procedure with Quantimet
(Zeiss, Germany) language. The parameters were calculated as function of Zoledro-
nate concentration.
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Figure 5.2: The bone density measured along the long axis of the implant is measured
in the two zones delimited by the red boxes.
5.3.8 µ-CT
Forty femurs were scanned by µ-CT before preparing them for the pullout test. A
Scanco Medical µ-CT40 scanner (Scanco Medical, Bassersdorf, Switzerland) was used
at 70 kV with slices every 16 µm. Using the SCANCO software, the trabecular bone
density was calculated around the implant using concentric rings centered on the
cylindrical implant. The radius increment between two successive rings was 6 µm.
The bone density is then calculated as the ratio of the number of voxels belonging
to the trabecular bone and the total number of voxels belonging to the total volume
of the cylindrical ring.
Moreover, the bone density was measured along the long axis of the implant in a
500 µm wide zone above and below the implant (the measuring zones are shown in
red boxes in Figure 5.2).
5.3.9 Sample preparation for pullout
After carefull removal of all tendons and other soft tissues around the emerging part
of the implant, a mould was made out of PMMA for each bone, in order to evenly
distribute the stresses on the condyle and therefore pullout the implant from the
condyle by only stressing the bone-implant interface.
The molding was made in two steps (see Figure 5.3). The first step is made by
protecting the implant with a PVC ring in order to avoid the liquid PMMA pouring
into the implant. The femur is then fixed on the base plate. Just enough liquid
was poured into the mould so that the lower part of the bone was in contact with
the polymer (Figure 5.3(a)). The mould is then placed on ice, in order to slow
down the polymerisation rate and therefore the maximum temperature reached in
the polymer. This caution was taken in order to avoid overheating the bone tissue.
Once the polymer was solidified, the bone is carefully removed. The PVC ring is
removed by drilling the PMMA so that the hole is larger than the pullout cylinder.
In a second step, the bone glued on the PMMA print is placed again in the mould
and placed on ice. The mould is filled with liquid polymer and let for complete
polymerisation (Figure 5.3(b)) on ice.
Once the polymer was hardened, the block containing the bone was let in the fridge
for a period of 24 hours to stabilize the polymer before pullout. The pullout cylinder
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Seal
First part of the moulded plastic
Condyle
Implant
(a) Molding of the first half of the molding
Second part of the moulded
plastic
First part of the moulded plastic
(b) Molding of the scond half of the molding
Second part of the moulded
plastic
First part of the moulded plastic
Pullout Pin
(c) Adding of the pullout cylinder
Figure 5.3: Manufacturing of the mold for every femur, to guarantee the alignement
of the implant and the pullout force.
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Figure 5.4: The embedded femur is placed in a steel frame. This frame is mounted
onto a tensile testing machine.
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Figure 5.5: Exemple of the Force-Displacement curve of the pullout test of a coated
implant.
was then glued with Loctite (Henkel, Avon, USA) and inserted into the implant (see
Figure 5.3(c)).
5.3.10 Pullout Test
A tensile testing machine UTS Testsystem (UTS, Switzerland) equipped with a
1000 N gauge was used and the implant was pulled out with a steady speed of 1
mm/min. Displacement versus force was registered and used for the determination
of the maximal pullout force.
The embedded femur is placed in a tensile testing machine. The pullout cylinder is
firmly attached to the moving part of the testing machine and pulled out. The whole
sample preparation and the pullout setup are planned in a way so that the long axis
of the implant is aligned with the pullout force (Figure 5.4).
The maximal pullout force Fmax is defined as the maximal force reached before the
interface between implant and bone breaks. This rupture is characterized by a sharp
drop in the measured force (see Figure 5.5), because the displacement speed is con-
stant.
Preliminary tests were performed to verify that the glued interface between pullout
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cylinder and implant is strong enough to withstand the pullout force.
5.3.11 Statistics
One-way ANOVA and Student’s t-test were used to determine the statistical signi-
ficance of the results. All the slices obtained for each condyle were considered as
repetition measurement for this condyle. A probability value of P≤0.05 was con-
sidered to be statistically significant. The calculations were performed using the
software XLSTAT 4.6 (Addinsoft, Paris, France).
5.4 Results
5.4.1 Bone density measured by SEM
Normal rats
The SEM pictures shown in Figure 5.6, clearly illustrate the positive effect of Zoled-
ronate coated implants on the peri-implant bone density. In the case of the coating
containing no Zoledronate, the peri-implant bone density is low and the bone does
not grow around the implant. Whereas in the case of the implant containing 2.1 µg
of Zoledronate, the bone grows around the implant and therefore the peri-implant
bone density is high.
Figure 5.7 shows the bone density as a function of the distance from the surface
of the implant at different Zoledronate concentrations. In the first 20 µm around
the implant, three behaviors can be observed. First, the two lowest Zoledronate
concentrations (0.2 and 2.1 µg/implant) result in the highest bone densities with
a steep decrease with increasing distance from the implant, but still above all the
other cases (P<0.003). Secondly, the implant loaded with 8.5 µg/implant shows a
lower (P<0.002) but steadier density than the two cases described above. Thirdly,
the bone density around the implant either loaded with the highest Zoledronate con-
centration (16 µg/implant) or the implant without Zoledronate has the lowest value.
These two cases are statistically not different from each other in the first 20 µm
around the implant. Nevertheless, these two cases follow different trends. The bone
density around the implant without Zoledronate is decreasing while the bone density
around the implant containing 16 µg/implant Zoledronate is increasing as a function
of distance.
Between 40 and 80 µm the situation changes. The highest bone density is obtained
with an intermediate Zoledronate concentration (2.1 µg/implant). The bone around
the implant loaded with 0.2 µg/implant becomes less dense that the bone around the
implant loaded with 8.5 µg/implant (P<0.05), thus inverting the situation observed
closer to the implant. The bone around the implant without any Zoledronate shows
the lowest density of all (P<0.01), about 30% lower than the lowest bone density ob-
tained with the Zoledronate loaded implants. The bone density around the implant
containing the highest Zoledronate concentration is steadily increasing and reaches
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(a) 0 µg Zoledronate per implant
10x
(b) 2.1 µg Zoledronate per implant
10x
(c) 0 µg Zoledronate per implant
23x
(d) 2.1 µg Zoledronate per implant
23x
Figure 5.6: SEM pictures of two condyles of normal rats at magnification of 10x
and 23x. a) the bone structure of a condyle implanted with an HA coated implant
containing no Zoledronate and b) the bone structure of the condyle containing an
implant coated with HA grafted with 2.1 µg of Zoledronate. The same implants and
their peri-implant bone are shown in c) and d) for the coatings loaded with 0 µg and
2.1 µg of Zoledronate respectively, at a magnification of 23x.
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Figure 5.7: Bone density as function of the distance from implant surface in normal
rats at different Zoledronate concentrations. Close to the implant, the peri-implant
bone density is the highest when 0.2 and 2.1 µg/implant of Zoledronate are present
in the coating. When higher Zoledronate per implant quantities are present in the
coating, the density decreases until reaching the same level as when no Zoledronate
is present. At 200 µm from the implant, the peri-implant bone density is the highest
when 2.1 to 16 µg/implant Zoledronate are present in the coating. An intermediate
density level is obtained with 0.2 µg/implant, while the lowest density is reached
when no Zoledronate is present (mean ± sem).
the same density as the bone around the implant containing 0.2 µg/implant.
From 80 to 200 µm, the bone density around the implants containing Zoledronate
from 2.1 to 16 µg/implant converges to a common density of 0.63. The Zoledronate
free implant reaches a steady bone density of 0.35 and is statistically different from
all Zoledronate containing cases (P<0.0001). The 0.2 µg/implant coating leads to a
steady bone density of 0.52 and is statistically different from the other Zoledronate
containing cases (P<0.028).
The bone density obtained around implants loaded with 0.2, 2.1 and 8.5 µg/implant
is statistically significantly denser than in all the other doses. Only at longer dis-
tances, the difference becomes statistically not significant.
In normal rats, the bone density taken at 1’400 µm is similar for all Zoledronate
content.
OVX rats
The SEM pictures shown in Figure 5.8, clearly illustrate the positive effect of Zole-
dronate coated implants on the peri-implant bone density in OVX rats. In the case
of the coating containing no Zoledronate, the bone peri-implant density is low and
the bone does not grow around the implant. Whereas in the case of the implant
containing 16 µg of Zoledronate, the bone grows around the implant and therefore
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(a) 0 µg Zoledronate per implant
10x
(b) 16 µg Zoledronate per implant
10x
(c) 0 µg Zoledronate per implant
23x
(d) 16 µg Zoledronate per implant
23x
Figure 5.8: SEM pictures of two condyles of OVX rats at magnification of 10x and
23x. a) the bone structure of a condyle implanted with an HA coated implant
containing no Zoledronate and b) the bone structure of the condyle containing an
implant coated with HA grafted with 16 µg of Zoledronate. The same implants and
their peri-implant bone are shown in c) and d) for the coatings loaded with 0 µg and
16 µg of Zoledronate respectively, at a magnification of 23x.
the peri-implant bone density is high.
The influence of the Zoledronate content on the bone remodeling is shown in Figure
5.9, where the bone density is plotted versus the distance from the implant’s coating.
In the first 20 µm, the densities around the implant loaded with any Zoledronate
concentration is higher than the bone density around the implant without Zoledro-
nate. In the zone between 20 and 40 µm, the bone densities follow different paths
in a Zoledronate dose dependent manner. The implants loaded with 8.5 and 16 µg
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Figure 5.9: Bone density as function of the distance from implant surface in OVX
rats at different Zoledronate concentrations. Close to the implant, all the implants
containing Zoledronate lead to a high bone density. With increasing distance, the
bone density decreases around the coatings containing the two lowest Zoledronate
concentrations, while the bone density increases around the implants containing the
two highest drug concentrations (mean ± sem).
Zoledronate increase slightly the bone density with increasing distance, while the
three other cases generate a decrease in bone density with increasing distance. This
trend continues till 80 µm and ends with the densities reaching two plateau values
depending on the Zoledronate content of the coating. On one hand, the two highest
Zoledronate concentrations lead to bone densities which reach a plateau located at a
bone density of 0.61, while the three other cases reach a plateau around 0.44, close
to the density obtained around the implants containing 0 µg.
Close to the implant, the bone density around the implants containing 0.2, 2.1 and
16 µg/implant is statistically higher than the bone density around the implants con-
taining 0 µg Zoledronate (P≤0.05). With increasing distance two groups of implants
appear which are statistically different: the first groups includes the three lowest
Zoledronate contents (0, 0.2 and 2.1 µg/implant) which decreases with the distance
to the implant’s surface to reach a value of 0.4, while the other group (including
the two highest Zoledronate doses) reaches a density of 0.6 (P≤0.05). In the case of
OVX rats, only the highest Zoledronate content increases slightly the bone density
at a distance of 1’400 µm when compared to all the other cases.
Bone implant contact
The SEM pictures (Figure 5.10) show the interface between bone and coating con-
taining 2.1 µg of Zoledronate implanted in a normal rat. The contact is very close
and at some points (arrow), it looks like the bone has grown into the coating.
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Figure 5.10: SEM pictures of the bone-coating interface around an implant coated
with 2.1 µg of Zoledronate implanted in a normal rat. The coating is shown in white,
while the bone is grey. At some points (arrow), the bone seems to grow inside the
coating.
5.4.2 Histomorphometry based on SEM
Normal rats
Zoledronate coated implants influence 4 histomorphometric parameters (FFS, NFS,
NNS, Skeleton length) in a concentration depending manner (Figures 5.11(a), 5.11(c),
5.11(e) and 5.12(a)) while 2 parameters (NF and FEC) were influenced only by one
concentration (Figures 5.12(c) and 5.12(e)). FFS, NFS and NNS are decreasing with
increasing Zoledronate concentration. Statistically two groups become visible : at
concentration of 2.1 µg/implant, the parameters are close to 0 µg/implant while at
higher Zoledronate concentrations FFS, NFS and NNS are lower (P<0.05).
The skeleton length significantly increases with increasing Zoledronate concentration
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compared to control except for the 0.2 µg/implant coating.
The parameters NF and FEC show a different profile. In both cases, the values for
the bone treated with 0.2 µg/implant are statistically different from all the other
cases (P<0.019).
OVX rats
Zoledronate coated implants influence 4 histomorphometric parameters (FFS, NFS,
NNS, Skeleton length) in a concentration depending manner (Figures 5.11(b), 5.11(d),
5.11(f) and 5.12(b)) while 2 parameters (NF and FEC) were influenced only by one
concentration (Figures 5.12(d) and 5.12(f)). FFS, NFS and NNS are decreasing with
increasing Zoledronate concentration. Statistically two groups become visible : at
concentration of 0.2 µg/implant, the parameters increased while at higher Zoledron-
ate concentrations and for control, FFS, NFS and NNS decreased.
The skeleton length significantly increases with increasing Zoledronate concentration
(P≤0.015).
The parameters NF and FEC show a different profile. In both cases, the values for
the bone treated with 0.2 µg/implant are statistically different from all the other
cases (P<0.031).
5.4.3 Pullout
Normal rats
The maximal pullout force (Figure 5.13) increases with increasing Zoledronate con-
centration up to 2.1 µg/implant in normal rats. At higher doses, the maximal pullout
force decreases with increasing Zoledronate concentration.
Statistically, the coating containing 2.1 µg Zoledronate reaches a significantly higher
pullout force than the case containing 8.5 µg (P=0.0148) and the case containing 16
µg of Zoledronate (P=0.0223). The other cases are not statistically different from
each other.
OVX rats
The maximal pullout force increases with increasing Zoledronate concentration up
to a doses of 8.5 µg/implant (Figure 5.14) for OVX rats. The maximal pullout force
of the implants loaded with 16 µg is decreased as compared to the pullout forces
obtained with 2.1 and 8.5 µg/implant.
Statistically, the coating loaded with 8.5 µg Zoledronate lead to an increase of the
maximal pullout force compared to the pullout force obtained with the implant not
containing any Zoledronate (P ≤0.05). The other cases are statistically not different
from each other.
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Figure 5.11: Histomorphometric parameters as function of the Zoledronate concen-
tration. Three parameters are dose-dependently influenced by Zoledronate. FFS,
NFS, NNS are decreased by increasing Zoledronate concentration. Note that the
scales can be different between identical parameters measured for the normal and
the OVX rats (mean ± sem).
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Figure 5.12: Histomorphometric parameters as function of the Zoledronate concen-
tration. The skeleton length is increased with the Zoledronate content of the coating.
NF and FEC are only influenced by the coating containing 0.2 µg/implant. Note that
the scales can be different between identical parameters measured for the normal and
the OVX rats (mean ± sem).
- 76 -
Chapter 5
0
300
250
200
150
100
50
M
a
xi
m
a
l P
u
llo
u
t 
Fo
rc
e
 [
N
]
0.20 162.1 8.5
Zoledronate content [µg/implant]
Figure 5.13: Pullout force as function of Zoledronate content of the coating for
normal rats. At low Zoledronate concentrations, the pullout force increases with
increasing Zoledronate content of the coating. The pullout force reaches a maximum
with a Zoledronate content of 2.1 µg/implant. By further increasing the Zoledronate
content of the coating, the pullout force decreases and reaches levels lower than when
no Zoledronate is present (mean ± sem).
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Figure 5.14: Pullout force as function of Zoledronate content of the coating for OVX
rats. At low Zoledronate concentrations, the pullout force increases with increasing
Zoledronate content of the coating. The pullout force reaches a maximum with a
Zoledronate content of 8.5 µg/implant. By further increasing the Zoledronate content
of the coating, the pullout force decreases (mean ± sem).
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Figure 5.15: The data obtained with the µ-CT allows to build a 3D view of the
implanted condyle. The implant is shown in grey, the bone in yellow and a region
of interest (ROI) in red. The ROI can be numerically extracted and shown without
the implant, revealing the contact area between bone and implant
5.4.4 Bone density measurement by µ-CT
Using the software provided with the µ-CT, the 3D structure of the condyle could be
build (Figure 5.15). Moreover, it is possible to visualize the bone-implant interface.
Normal rats
The influence of the Zoledronate content in the coating on the peri-implant bone
density has been measured along the long axis of the implant (Figures 5.2 and 5.16).
In the case of normal rats, the bone density is increasing with the Zoledronate con-
tent of the coating up to the content of 8.5 µg/implant. Further increase of the
Zoledronate content decreases the bone density. None of the densities is statistically
different from each.
OVX rats
In the case of OVX rats, the bone density around the implant containing 0.2 µg of
Zoledronate is lower than when no Zoledronate is present (not significant). By further
increasing the Zoledronate content of the coating, the bone density increases to reach
a plateau with bone density generated with a coating containing 8.5 µg/implant.
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Figure 5.16: The bone density measured along the long axis of the implant is shown
as function of the Zoledronate content of the coating for normal and OVX rats.
The bone density increases with increasing Zoledronate concentration, to reach a
maximum at 8.5 µg/implant for the normal rats. For OVX rats, the bone density in-
creases with increasing Zoledronate content and reaches a plateau for the two highest
Zoledronate contents (mean ± sem).
Further increase of the Zoledronate content does not increase the bone density but
keeps it at the same value as the bone around the implant containing 8.5 µg of
Zoledronate. The implants containing the two highest Zoledronate contents generate
bone densities which are significantly higher than the bone densities generated around
the implants containing 0 and 0.2 µg of Zoledronate. In addition, the coating loaded
with 2.1 µg of Zoledronate generates a bone significantly denser than the bone around
the implants containing 0.2 µg.
5.4.5 Correlations between histomorphometry, density and
pullout force
Since the peri-implant bone density and the maximum pullout force are influenced
by the presence of Zoledronate, one could assume that there is a correlation between
bone density and mechanical stability of the implant. The correlation between the
pullout forces and the densities taken at 18 µm from the implant is shown as example
in Figure 5.17. These correlation data are shown in Figure 5.18 as function of the
distance from the implant surface. The correlation factor R2 is calculated with the
pullout force (as function of Zoledronate content of the implant) versus the density
taken at 6 distances from the implant’s surface (6, 12, 18, 48, 57 and 200 µm) and
as a function of the Zoledronate content of the implant.
For normal rats, the correlation between the pullout force and the density of the
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Figure 5.17: Correlation between the pullout forces and the densities (measured at
18 µm from the coating) for the different Zoledronate contents in the coatings in
normal rats (mean ± sem).
bone taken at a distance of 6 µm from the implant’s surface is very good (R2=0.87).
Interestingly, when the bone density is taken at a greater distance from the implant,
the correlation decreases so that at 18 µm the correlation factor became 0.77 and
progressively 0.49 at 57 µm. When the bone density used for the correlation calcu-
lation is taken at 200 µm, the correlation factor is as low as 0.02.
For OVX rats, the correlation is very good for the distances of 6, 12 and 18 µm
with R2 values of 0.92, 0.92 and 0.81 respectively. With increasing distance to the
implant’s surface, the correlation curve drops rapidly to reach values close to zero
at distance of 48 and 57 µm. The correlation becomes slightly better at 200 µm
reaching 0.16. Using a powerlaw to fit the different histomorphometric parameters
with the pullout maximum force, we obtained the correlation factors shown in Table
5.3. In the case of normal rats (see Figure 5.19), the parameters FEC and NF did
not show any correlation with the maximum pullout force (R2 of 0.22 and 0.21 re-
spectively). The skeleton length, NNS, NFS and FFS are strongly correlated to the
maximum pullout force (R2 of 0.87, 0.92, 0.92 and 0.86 respectively). None of the
histomorphometric parameters showed a correlation above 0.50 for the OVX rats (see
Figure 5.20).
5.5 Discussion
The goal of this study was to determine the Zoledronate-HA coating leading to an
optimal peri-implant bone density distribution, optimal from the point of view of
implant fixation.
The most remarkable result of this study was to show the existence of a window of
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Figure 5.18: Correlation factor between bone density taken at distance d from the
implant’s surface and pullout force for normal and OVX rats.
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Figure 5.19: Correlation between some histomorphometric parameters and the pul-
lout force for normal rats
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Figure 5.20: Correlation between some histomorphometric parameters and the pul-
lout force for OVX rats
Table 5.3: Correlation factor of the histomorphometric parameters data fitted with
the maximum pullout force by a power law
Parameter Normal OVX
FEC 0.22 0.21
NF 0.21 0.20
Skeleton length 0.87 0.25
NNS 0.92 0.38
NFS 0.92 0.38
FFS 0.86 0.43
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Zoledronate content (0.2 to 2.1 µg/implant for normal rats and 0.2 to 8.5 µg/implant
for OVX rats) in which the mechanical fixation of the implant is increased.
The selection of the Zoledronate contents in the coatings was based on the idea to
use coatings which deliver a Zoledronate quantity leading to a concentration close to
the safety concentration determined in Chapter 3.
5.5.1 Normal rats
Tengvall99 showed an increase of 28% of the pullout force of steel screws inserted
in rat tibias by using a fibrinogen/pamidronate/ibandronate coating. In the present
study, the implants containing 2.1 µg of Zoledronate induced an increase in pullout
force up to 42% compared to implants without Zoledronate. This difference may be
explained by the fact that Zoledronate is more efficient in decreasing bone resorption
than the bisphosphonates used by Tengvall. The combination of HA and Zoledron-
ate is probably more favorable than fibrinogen and bisphosphonate in the point of
view of orthopedic implant fixation. However at higher Zoledronate concentrations,
the pullout force decreased by 35% when compared to implants without Zoledron-
ate. High Zoledronate concentrations might then probably affect bone formation as
shown in vitro74 (Chapter 3). This is illustrated by the fact that in the first 20 µm
around the implant, the bone density is the same for the coating without Zoledro-
nate and the one containing the highest Zoledronate quantity. Another supporting
observation for this explanation is that with increasing distance, the bone density
around the implant loaded with 16 µg is increasing whereas the control case shows
a decreasing bone density (Figure 5.7 and 5.9). This effect could be due to the di-
lution of the Zoledronate with increasing distance. Indeed, this could also explain
why the implant with the highest Zoledronate content reaches the same density at
200 µm from the implant as the two intermediate Zoledronate content (2.1 and 8.5
µg/implant), while the two lowest (0 and 0.2 µg/implant) are lower by 17% and by
45% respectively compared to the highest density.
The latest observations and the pullout results would mean that a correlation ex-
ists between bone density and mechanical stability for normal rats and OVX rats.
The correlation between pullout force and density decreases with the distance from
the coating at which the density is measured. The first 20 µm are then of utter-
most importance for the mechanical fixation of an implant. Thereby, the approach
of increasing the peri-implant density by a local drug delivery becomes even more
justified.
In most in vivo studies, the effect of bisphosphonates on the histomorphometry of
bone was an increase in trabecular number and thickness and a decrease of trabecular
separation91, 64, 54. In our study, none of those parameters seem to be altered by the
presence of Zoledronate. The parameters FFS, NFS, NNS and skeleton length illus-
trate a narrowing of the weaved structure of trabecular bone. These differences may
be due to the fact that in the other studies, the bisphosphonate passed through the
gastro-intestinal apparatus and the blood stream before reaching the bone, while in
our case, the bisphosphonate was directly put into contact with the bone through the
means of the HA coating. The delivery type would probably influence the bioavail-
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ability and the distribution of bisphosphonate in the bone and thus the peri-implant
bone density and morphology.
Interestingly, the influence of the lowest Zoledronate concentration on FEC and NF
cannot be explained at the present time, but could be due to lower number of speci-
mens in this group. More information of the dynamic behavior of the Zoledronate-HA
coated implants could be achieved by studying more timepoints.
The influence of the Zoledronate content on the different histomorphometric para-
meters are the same in the normal and OVX group.
The correlation between the pullout force and the histomorphometric parameters
skeleton length, NNS, NFS and FFS is high in normal rats. This correlation is not
found for the OVX rats.
The correlation between the density and maximal pullout force is better for the dens-
ities measured by SEM than for the ones measured by µ-CT. This can be explained
by the fact the metallic implant produces an artifact which will have a tendency to
increase the bone density, especially at the bone-implant interface. Moreover the
artifact effect is anisotropic.
5.5.2 OVX rats
To simulate a peri-implant resorption, an osteoporotic rat model was used. The
osteoporosis was induced by an ovariectomy. Even though the causes for osteoporosis
and for peri-implant resorption are not the same, the resorption takes place in both
cases through an increased osteoclastic activity. Since the proposed treatment acts
on the number of active osteoclasts, independently of the causes of activation, the
choice of the model is reasonable. Moreover, this model is also useful in a possible
drug delivery system application for osteoporotic patients.
The influence of the Zoledronate coated implants on the peri-implant bone is certainly
different in OVX rats than in normal rats. By comparing the bone density profile as
function of the Zoledronate content (Figures 5.7 and 5.9), one can easily see that the
highest bone density is obtained with different Zoledronate concentrations for each
rat group (normal rats versus OVX rats). In the case of the OVX rats, the highest
density is obtained with the two highest Zoledronate contents, a situation opposite
to what was observed with normal rats. Further away from the implant, the bone
density in the normal rats is the highest around the implants containing the three
highest Zoledronate concentrations. When looking at the mechanical stability, the
above mentioned discrepancy is also present. The highest pullout force is obtained
in normal rats with a Zoledronate content of 2.1 µg/implant while 8.5 µg/implant
are needed in the OVX rats. By increasing the Zoledronate amount, the mechanical
stability decreases strongly in the case of normal rats and to a lesser extend for OVX
rats.
At 200 µm from the implant’s surface in normal rats, the three highest Zoledronate
contents generate the highest bone density. In OVX rats, only the two highest
contents lead to the highest bone density.
The bone density in the control rats belonging to the OVX group was slightly higher
than in the normal group, but not significantly (P=0.9), when measured between 0
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and 200 µm away from the coating. One would have expected the opposite effect
due to the induced osteoporosis. But the higher density in the OVX group can be
explained by the body weight of the rats which is significantly higher for the OVX
rats. The measurements with the µ-CT were performed to quantify the bone density
around the implants before subjecting them to the pullout tests. Moreover, the
contact surface between the bone and the implant should have been measured in
order to verify if the presence of Zoledronate had an influence on the failure stress.
Due to the interaction between the metallic implant and the x-rays used in the µ-CT,
the resolution close to the implant was low, avoiding to perform these calculations
with sufficient precision. In the meanwhile, the density measurements along the
long axis confirm the Zoledronate dose effect on the bone density. An interesting
aspect of the Zoledronate local use, is that the coatings loaded with 2.1 and 8.5 µg
of Zoledronate allow to improve the osteoporotic bone quality to a point that the
pullout force of those two cases is above the pullout force obtained with the 0 µg
implants in normal rats. This means that the same fixation quality of an implant
in osteoporotic bone can be obtained as in a normal bone by adding Zoledronate in
the coating of the implant. The density measurements at 1’400 µm away from the
surface of the coatings shows no influence of the Zoledronate contained in the coating
of the implant, meaning that the effect of the Zoledronate-HA coating stays local.
5.6 Conclusion
This study was able to establish the proof of concept for orthopedic implants used
as drug delivery system. The local bisphosphonate delivery from a calcium phos-
phate coating allowed to increase the mechanical fixation of an orthopedic implant.
Moreover, we showed that the increase in peri-implant bone density is dependent
on the Zoledronate content of the coating. The Zoledronate content of the coating
which leads to the highest mechanical stability of the implants is lower for normal
rats than for OVX rats. The Zoledronate release from the coating positively influ-
ences the structure of the trabecular bone. We showed that the mechanical stability
of an implant is correlated to the bone density in the 20 µm of bone around the
implant advocating for a local delivery of the bisphosphonate.
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Conclusions and perspectives
6.1 Conclusions
The purpose of this thesis was to develop a new concept of orthopedic implant, tak-
ing into account the biological nature of a major failure mode which is the proximal
peri-implant osteolysis. To achieve this goal, the use of a bisphosphonate incorpor-
ated into the HA coating stem of an hip implant was suggested.
The first step in the development of an orthopedic implant used as drug delivery
system was to preclinically test the effect of bisphosphonate on the peri-implant
bone remodeling. The numerical approach showed that the bisphosphonate coating
may allow to decrease the bone resorption and the micromovements at the bone-
implant interface. Therefore the evolution towards osteolysis and fibrous tissues at
the bone-implant interface would be adverted or at least delayed which would posit-
ively influence the THR outcome.
One hypothesis in the numerical implementation of the drug effect was that the bi-
sphosphonate had no effect on the bone formation. Indeed, the in vitro study showed
that Zoledronate concentration below 10 µM did not affect the proliferation of the
cells nor the ALP activity, that is one of the first steps in bone formation. Even
though the purpose of using bisphosphonate coated implants is to avoid the form-
ation of metallic wear particles, this possibility cannot be ruled out. Therefore, a
concern to address, is a possible negative interaction, from the point of view of the
osteoblasts, between the metal particles and the bisphosphonate. The culture of os-
teoblasts with a medium containing titanium particles and Zoledronate, showed no
synergetic effect of Zoledronate and titanium particles on osteoblasts.
Once a Zoledronate safety-concentration was determined below which no cytotox-
icity was observed, the Zoledronate diffusion in bone needed to be quantified in the
context of the local drug delivery system. In the limitation of the in vitro diffusion
experiments, the Zoledronate quickly entered the bone and stayed in the endosteal
bone where its action was anticipated. This was one of the major positive results
that based the motivation in the development of orthopedic implant as drug delivery
system. It could also be shown that the Zoledronate did not leave the bone in the
tested conditions.
Using the Zoledronate safety-concentration and knowing the diffusion behavior of
Zoledronate in bone both determined in vitro, an in vivo study was designed to test
the proof of concept for an orthopedic implant used as drug delivery system. The in
vivo study demonstrated the effectiveness of the concept of using a local bisphosphon-
ate delivery from an HA coating in order to increase the mechanical fixation of an
orthopedic implant compared to HA coating containing no Zoledronate. Moreover,
the increase in peri-implant bone density was dependent on Zoledronate content of
the coating. The Zoledronate released from the coating positively influenced the
Chapter 6
structure of the trabecular bone and therefore the mechanical stability of the im-
plants. A very important result for the motivation of an orthopedic implant used as
drug delivery system was that the mechanical stability of the implant was correlated
to the density of the bone found in the first 20 µm around the implant. This re-
markable result clearly advocated in favor of a local delivery system to increase the
mechanical stability of orthopedic implant.
The numerical model, used to predict the remodeling around a hip implant, forecas-
ted a 12% increase in peri-implant bone density when bisphosphonate was locally
used. The in vivo study showed a peri-implant bone density increase up to 30%. The
remarkable match between numerical and in vivo results validates then the approach
of using the developed model. Therefore preclinical testing can be an effective tool
to quantify the effect of a drug affecting bone remodeling.
The present study opens the way of an eventual significative evolution in hip implant
design by an easy transformation of currently existing coated implant designs. By
grafting Zoledronate onto the HA coating of the stem, the THR outcome could be
significantly increased.
6.2 Perspectives
Based on the proof of concept obtained in this thesis for an orthopedic implant used
as drug delivery system, further experiments need to be performed before a clinical
trial might be considered. The in vivo rat experiment should be repeated with a
longer implantation time (3 to 6 months) in order to verify that the decrease of
bone resorption would not finally impair implant stability by avoiding the renew of
micro-cracked bone into micro-crack free bone. Moreover, it would be interesting to
quantify the peri-implant bone remodeling at different time points in order to eval-
uate the bone evolution.
The murine bone remodeling is different than the human one, it would then be im-
portant to perform in vivo experiments in larger animals such as dogs or sheep, well
used as models in orthopedics. With these models, custom made hip implant could
be inserted in the animals femur. The effect on implant fixation of the orthopedic
implant used as drug delivery system could be evaluated in situations where both
bisphosphonate and mechanical stimuli are present. Finally, if these in vivo studies
furnish positive results regarding the decrease of peri-implant bone resorption and
the increase of implant fixation, determination of Zoledronate concentration to be
used for humans could be done in clinical situations where screws or nails coated
with HA and Zoledronate are used for fracture treatment. This situation would be
favorable from a safety point of view as these implants are not intended to perman-
ently stay in bone.
Even though osteoporosis is a systemic condition, a solution could be imagined where
in addition to a systemic treatment, a local drug delivery system could be applied
in the parts of the skeleton which are strongly affected by osteoporosis (very low
bone density) or parts of the skeletons which experience a high risk of fracture. This
system could consist of small HA beads containing bisphosphonates which would
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be introduced into the bone to be treated by minimal invasive surgery. Indeed, as
demonstrated in the in vivo study with osteoporotic rats, the local drug delivery of
Zoledronate significantly increased the bone density and its mechanical properties.
Finally, in this thesis the catabolic bone process was targeted with the use of bi-
sphosphonates. The concept of orthopedic implant as drug delivery system could
also target the anabolic bone process. To this purpose, the orthopedic implant could
be coated with bone morphogenic protein (e.g. BMP-2) as this protein has been
shown to enhance bone healing in different clinical situations.
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